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CRISPR-Cas systems endow bacteria and archaea with adaptive
immunity against foreign genetic threats, like phages and plasmids. These
immune systems are comprised of CRISPR-associated (Cas) protein effectors
and DNA-based storage of immunological memories in the CRISPR array. The
CRISPR array is a series of direct repeats intercalated by variable spacer
sequences (~30bp) of foreign origin. Upon infection, spacers are excised from
the foreign genome and integrated into the array. The array is then transcribed
and parsed into individual CRISPR RNAs, each containing a single spacer
sequence, which are used by Cas nucleases to identify foreign nucleic acids for
destruction. Thus, spacer sequences represent molecular memories that serve to
define the specificity of the CRISPR immune response.
New spacers are added invariably to the 5’ end of the array; therefore, the
first spacer matches the most recent foreign invader. How this order is
established and whether this highly polarized order of spacer insertion influences
CRISPR-Cas immunity has not been explored. In my thesis work, I showed that
conserved nucleotides within the leader, a sequence located immediately
upstream of the CRISPR array, specify the site of new spacer integration with
high fidelity. Mutation of this sequence results in erroneous incorporation of new

spacers into the middle of the array. To interrogate the importance of polarized
spacer addition, I compared the immune responses generated by CRISPR
systems containing wild type and mutant leader sequences. I showed that
spacers added through polarized acquisition give rise to more robust immunity
than spacers added to the middle of the array. This demonstrated that the
CRISPR-Cas system specifies the site of spacer integration to optimize the
immune response against the latest and most immediate threat to the host.
Because addition of new spacers pushes existing spacers further
downstream, each spacer added to the CRISPR array weakens the immunity
provided by already existing spacers within the array. How CRISPR systems
address this conundrum had not been explored. In this thesis work, I showed that
CRISPR systems exhibit significant natural variation in the rates of spacer
acquisition and thereby can modulate the lifespan of existing spacers in the
array. Fast-adapting systems can respond quickly to new invaders, but existing
spacers rapidly lose their potency. In contrast, slow-adapting systems preserve
potency of existing spacers at the cost of reduced rates of spacer acquisition. I
showed that bacteria have overcome these tradeoffs by harboring multiple
CRISPR systems that acquire new spacers at different rates. I also found that
leader-repeat junctions serve as a means for spacer acquisition complexes to
discriminate between related CRISPR arrays. I propose a model whereby
bacteria can harbor two related CRISPR systems as a means to form both shortand long-term immunological memories against foreign invaders.

Bacteria were once thought to possess only primitive forms of innate
immunity, but this notion was turned on its head by the discovery of the CRISPRCas immune system. My thesis work has revealed a deeper complexity of
bacterial immunity and evolution by demonstrating that CRISPR systems
functionally organize molecular memories of past invaders as a means to confer
optimal immunity to the host.
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CHAPTER 1: INTRODUCTION TO THE CRISPR-CAS IMMUNE RESPONSE
1.1 INTRODUCTION
Prokaryotic organisms are frequently exposed to both beneficial and
parasitic foreign nucleic acids1. On one hand, this allows organisms to access
and incorporate diverse genetic material, like antibiotic resistance genes
encoded on plasmids or virulence factors encoded by temperate phages. On the
other, this renders cells vulnerable to parasitic elements that compromise the
fitness of the population, like plasmid-encoded transposons or virulent phages.
To balance these costs and benefits, bacteria and archaea have evolved a
number of pathways to curate the nucleic acids entering the cell. These
pathways have profound implications for the evolution of prokaryotic
populations1.
Clustered regularly interspaced short palindromic repeats (CRISPR) and
their associated genes (cas) encode one such mechanism by which cells restrict
incoming nucleic acids2,3. CRISPR-Cas systems have the unique ability to
heritably alter the host genome by incorporating small fragments of foreign
nucleic acids, known as spacers, in between the repeats of the CRISPR locus
(Figure 1.1.1)2. This process is known as spacer acquisition 4-6. Spacers are
transcribed and parsed into individual CRISPR RNAs (crRNAs), which guide
effector Cas nucleases to cleave cognate nucleic acids. Thus, spacer sequences
define the specificity of the CRISPR-Cas immune response, bestowing immunity
to both the host and its progeny2,3.
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Figure 1.1.1. General schematic of the spacer integration reaction.
The CRISPR array comprises a series of direct, semi-palindromic repeats
intercalated with variable spacer sequences of foreign origin. The array is
preceded by an AT-rich leader sequence. Integration of new spacers begins with
a concerted cleavage–ligation reaction that occurs preferentially at the leader end
of the first repeat, whereby the terminal 3′-OH of the protospacer carries out a
nucleophilic attack. Next, the repeat DNA is bent, and a second cleavage–ligation
reaction takes place at the spacer side of the repeat. The product of this reaction
is an intermediate in which the 3′ ends of a double-stranded (dsDNA)
protospacer are ligated to single-stranded DNA (ssDNA) repeat sequences. The
ssDNA repeats are presumably filled by DNA polymerase and ligated to complete
the spacer integration process.
Found in approximately 45% of bacteria and 85% of archaea, CRISPR
systems have been categorized by cas gene content into 2 classes, 6 types, and
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over 20 subtypes7. Each of the six types utilizes functionally distinct effector
complexes that mediate the destruction of foreign nucleic acids. Whereas Types
I, II, and V target DNA, Type VI targets RNA, and Type III targets both RNA and
DNA (Type IV systems have not been experimentally characterized yet)7. In
contrast, the core machinery that mediates spacer acquisition, encoded primarily
by cas1 and cas2, is relatively well conserved across the different types. Spacer
acquisition can be conceptually divided into two phases: protospacer capture and
spacer integration. During the first phase, protospacers (spacer sequences in the
invading genome) must be selected and extracted from foreign genomes. In the
second phase, spacers must undergo processing and incorporation into the
CRISPR locus. Recent studies have revealed several aspects of the molecular
mechanism of spacer acquisition and how these correlate with the specific
targeting mechanism of each different CRISPR Type. Here, we review the
current models of spacer acquisition and discuss the future of the field, both in
terms of basic science research and technological applications.
1.2 INTEGRATION OF NEW SPACERS
The Cas1-Cas2 integrase
The Cas1-Cas2 complex is the core machinery that mediates spacer
acquisition. Cas1 is the most highly conserved Cas protein and can be found in
all six CRISPR Types7. It is believed that Cas1 evolved as the core enzyme of a
class of transposons called casposons and was eventually co-opted to form the
basis of the CRISPR-Cas immune system8. In the context of CRISPR immunity,
Cas1 interacts with Cas2 to form a complex that acts as the spacer integrase9-13.
3

This heterohexameric complex [(Cas12-Cas2)2] contains two separate DNAbinding regions, one that binds the incoming protospacer and one that binds the
CRISPR array. Once loaded with the incoming spacer, the Cas1-Cas2 complex
catalyzes two cleavage-ligation reactions, first at the leader-end of the first repeat
of the CRISPR array and subsequently at the spacer-end of the repeat12-14
(Figure 1.1.1). In this reaction, the terminal 3’-OH of each strand of the
protospacer DNA performs a nucleophilic attack on each end of the repeat DNA.
The product of this reaction is an intermediate in which the 3’ ends of a dsDNA
protospacer is ligated to ssDNA repeat sequences. These ssDNA “gaps” are
presumably filled by a DNA polymerase and then ligated, resulting in a
simultaneous spacer insertion and repeat duplication12-18.
Site-specific integration of new spacers
The integration of new spacers by Cas1-Cas2 is polarized, meaning that
new spacers are predominantly added to the leader-end of the CRISPR array.
For this reason CRISPR loci have been compared to molecular fossil records of
past infections, with the newest memories at the leader-end and the most
ancestral spacer sequences at the trailer-end 18. By ordering spacers
chronologically, CRISPR systems optimize their immune response against the
most recent invaders since leader-end spacers provide more robust immunity
relative to more downstream positions19. This has been proposed to be a bethedging strategy in which resources are prioritized to defend the host against the
most recent invader, which is also most likely to be the biggest threat to the
cell19,20. One potential mechanism underlying this phenomenon is the differential
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expression of crRNAs across the CRISPR array, which has been observed in
many CRISPR Types21-25. In one study of the Streptococcus pyogenes Type II-A
system, a two-fold difference was observed when comparing the abundance of
crRNAs originating from the same spacer sequence in the first or fifth position in
the array19. Given that a single Cas9 ribonucleoprotein can take hours to find its
target (according to single-molecule experiments)26 and that it is reported to be a
single-turnover enzyme27, it is possible that modest differences in crRNA
abundance can give rise to larger differences in the level of immunity afforded to
the host 19.
Several mechanisms have the potential to “re-activate” ancestral
memories that are positioned further downstream in the CRISPR array. Spacer
deletions have been frequently observed in laboratory and natural contexts 28,29.
Indeed, in one study of the Type II-A system from S. pyogenes, deletion of four
spacers from the 5’ end of the array was heavily selected for during phage
infection, which enabled a spacer in position 5 to be shifted to position 1 to
enable maximum levels of immunity 19. Alternatively, another study revealed that
internal promoters contained within spacer sequences can enable high
expression of downstream crRNAs 30. In addition, we speculate that is possible
that lower expression of downstream crRNAs that are unable to provide full
immunity could enable a primed immune response (see Primed Spacer
Acquisition section).
How this polarized addition of new spacers is achieved differs by CRISPR
Type (Figure 1.1.2). In Type I CRISPR systems, an α-helix of Cas1 makes
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sequence-specific contacts with the minor groove of the leader12,31, but this is not
sufficient to enforce leader-end spacer addition15. Rather, factors encoded by the
host genome are required for site-specific integration. In Types I-E and I-F, a
protein called Integration Host Factor (IHF) is required for polarized spacer
integration in vitro and is required for spacer acquisition in vivo. These Type I
leaders contain a conserved IHF binding site, and binding of this site by IHF
induces a topological change of the CRISPR array DNA. This creates the ideal
target substrate for the Cas1-Cas2 integrase specifically at the first repeat12,32.
Additionally, the Cas1-Cas2 integrase makes contacts with IHF as well as
upstream sequences in the leader as a result of DNA bending induced by IHF12
(Figure 1.1.2, top). This mechanism leads to a conundrum for Type I CRISPR
systems found in Gram-positive bacteria, which lack IHF homologs32. It is
possible that related DNA-bending proteins (i.e. HU or H-NS) could fulfill this role.
Indeed, an archaeal Type I-A system, whose host lacks IHF, exhibits leader
specificity for spacer integration in a manner dependent on as of yet unidentified
host factor(s) 33.

6

Figure 1.1.2. Two mechanisms for preferential spacer acquisition at the
leader end of the CRISPR array.
In the type I system, integration host factor (IHF) binds to a conserved binding
site in the leader and induces DNA bending, which enables the Cas1–Cas2
complex to perform the first cleavage–ligation reaction. Cas1–Cas2 makes
specific contacts with upstream and downstream sequences in the leader, as well
as with IHF. In the type II system, Cas1-mediated recognition of the leader
anchoring sequence (LAS) in the leader is sufficient for polarized spacer
integration.

Type II CRISPR systems, which are commonly found in Gram-positive
hosts34, also exhibit strictly polarized spacer integration2,14,19,35. In contrast to the
Type I machinery, the Type II Cas1-Cas2 complex can induce the necessary
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DNA topology for the spacer integration reaction without any additional host
factors13,14. Similar to the Type I system, an α-helix of the Type II Cas1 makes
sequence-specific contacts with the minor groove of the leader DNA (for Type II,
this is termed the Leader Anchoring Sequence, “LAS”)13,14,19. In contrast to Type
I, these contacts are sufficient to enforce leader-end spacer integration without
the need of any additional host factors (Figure 1.1.2, bottom)13,14,19. These
additional contacts between the LAS and Cas1 improve the kinetics of the
cleavage-ligation reaction at the leader-repeat junction, enforcing polarized
spacer addition13,14. Because the second cleavage-ligation reaction occurs at the
spacer-repeat junction, the target substrate is variable and this requires some
flexibility in the LAS-interacting domain of Cas1 for catalyzing the reaction13.
Probably as a result of this flexibility, in the absence of a proper LAS the Type II
CRISPR systems can undergo “ectopic spacer integration,” or integration of new
spacers in the middle of the array19.
1.3 PROTOSPACER CAPTURE
Identification of foreign nucleic acids
CRISPR systems can acquire self-targeting spacers from the host
chromosome18,36,37, which result in autoimmunity and cell death38-40. To avoid
this, CRISPR systems employ a variety of mechanisms to bias spacer acquisition
to foreign genetic elements.
CRISPR systems utilize the DNA repair machinery of the host, RecBCD in
Gram negative organisms17,36 and its homologue AddAB in Gram positives 41, for
the generation of spacer substrates. RecBCD, which binds free ends of dsDNA
8

to perform end resection during homologous recombination, stimulates spacer
acquisition from double strand breaks. This activity is limited by chi sites, which
are eight nucleotide sequence motifs that slow RecBCD activity. Because chi
sites are enriched in the host chromosome relative to phage or plasmid
genomes, this can serve as a mechanism to constrain spacer acquisition from
the host genome and differentiate self versus non-self DNA sources36,41. Further,
the free dsDNA end that is presented to the cell during infection by dsDNA
phages is exploited by the CRISPR system to preferentially acquire spacers from
the phage DNA (Figure 1.2.1), since the bacterial chromosome is circular and
lacks free DNA ends (with the exception of accidental dsDNA breaks, most
common at the terminus). This also biases the pool of acquired spacers to the
injected end of the phage genome, which results in the immediate recognition
and cleavage of the invading DNA at the very beginning of the infection resulting
in more effective immunity41. Although RecBCD is important for efficient spacer
acquisition, its degradation products are reported to be ssDNA fragments42,43.
Given that the in vitro spacer integration studies showed that dsDNA protospacer
substrates are markedly favored over ssDNA ones10-15,44, it remains unresolved if
and how RecBCD degradation products could be used for spacer integration
45,46

. Alternatively, it is possible to that the Cas1-Cas2 machinery physically

associates with RecBCD 47 to either directly uptake degradation products from
RecBCD 36 or to sample intact dsDNA upstream of RecBCD. Moreover, given
that spacer acquisition can occur in the absence of RecBCD 36 and AddAB 41, it
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is clear that alternative pathways exist for spacer generation, which will be an
interesting area of future study.

Figure 1.2.1. Spacers are acquired during viral DNA injection.
RecBCD in Gram-negative organisms (or AddAB in Gram-positive organisms)
generates substrates for spacer acquisition following the injection of viral DNA,
possibly by producing more invader DNA molecules that contain free ends.

There is also evidence that evolution has tuned CRISPR systems to avoid
deleterious levels of autoimmunity by limiting the rate of spacer acquisition. In
laboratory settings, successful acquisition of new spacers against phage is an
extremely rare event, estimated to occur in only 1 in 107 cells19,48,49. Spacer
acquisition from the host genome is equally rare and does not pose significant
fitness costs to the host. However, mutants with increased rates of spacer
acquisition have been shown to lead to higher levels of toxicity50, suggesting that
the rate of spacer acquisition has been evolutionary tuned to balance protection
benefits with autoimmune costs. To mitigate growth rate costs associated with
autoimmunity, it is also possible for spacer acquisition to be temporally regulated.
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Indeed, quorum sensing has been implicated as a regulator of CRISPR activity in
at least two species of bacteria51,52.
Selection of functional targets
Only a subset of sequences in foreign genomes can serve as functional
spacers because of Type-specific targeting requirements. In Types I and II, a
protospacer-adjacent motif (PAM) located at one of the flanks of the target is
required to license target cleavage and to prevent the cleavage of the spacer
sequence in the CRISPR array (repeats lack properly positioned PAMs)53,54.
While Type III flanking sequence requirements are more flexible 55-57,
transcription across the target is needed for targeting of the DNA58-61. To ensure
functional immune responses, CRISPR systems must select protospacers that
are flanked by the correct PAM or are actively transcribed.
In Types I and II, the spacer acquisition machinery preferentially samples
protospacers with functional PAMs. However, the two types employ different
mechanisms to accomplish this (Figure 1.2.2). In Type I-E, the Cas1-Cas2
complex has direct, sequence-specific interactions with the PAM that biases
acquisition to PAM-adjacent protospacers11 (Figure 1.2.2, top). In contrast, the
Cas1-Cas2 complex from the Type II CRISPR system does not exhibit any PAM
selectivity13,48. Instead, Cas9’s PAM-interacting domain enforces PAM-specific
spacer acquisition through direct interactions with the Cas1-Cas2 complex (as
well as the Type II accessory protein Csn2)48 (Figure 1.2.2, bottom). Spacer
acquisition has not been observed experimentally for many of the transcriptiondependent Type III CRISPR systems. A small fraction of Type III systems has
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been shown to harbor reverse transcriptase-Cas1 (RT-Cas1) fusion proteins.
Indeed, one such system has been observed to preferentially acquire spacers
from transcribed regions of genomes62,63. While the exact mechanism remains
unclear, it has been demonstrated that RT-Cas1 fusion proteins can acquire new
spacers directly from RNA transcripts. These RNA-derived spacers provide a
mechanism to ensure that their targets are transcribed and can be recognized by
the Type III RNA-guided nucleases.

Figure 1.2.2. Two mechanisms for selection of functional targets.
In the type I-E system, Cas1–Cas2 has inherent substrate preference for
protospacers with a canonical protospacer-adjacent motif (PAM). In type II, the
PAM-interacting domain of Cas9 (loaded with trans-activating CRISPR RNA
(tracrRNA), not shown) guides the Cas1–Cas2 complex (as well as the
accessory protein Csn2) in selecting protospacers.

1.4 PRIMED SPACER ACQUISITION
Pre-existing spacers can enhance the rate of spacer acquisition in a
sequence-dependent manner through a process known as primed spacer
acquisition, or priming (enhanced relative to “naïve acquisition,” in which no full
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or partially matching spacers are present in the CRISPR array). Priming can
arise from either perfectly matching spacers or spacers against mutated phages
(or related phages) with point mutations in the spacer region or PAM. Thus, once
a host acquires a single spacer against a phage, it becomes more likely to
subsequently acquire additional spacers from the vicinity of the priming target
region in the phage genome30,64. This feed-forward cycle is driven by close
associations and interactions between the spacer acquisition machinery and the
interference machinery. Indeed, the importance of these associations is
underscored by the existence of fusion proteins in which interference genes have
been fused to spacer acquisition genes, like the Cas2-Cas3 fusion protein
present in Type I-F systems 44,65.
As of yet, priming has only been observed for Type I CRISPR-Cas
systems, with the Types I-E and I-F systems as the best studied examples.
During Type I-E targeting, the crRNA-guided Cascade complex binds to a foreign
target in a PAM-dependent manner, upon which it recruits the nuclease Cas3 for
target destruction66. In addition to eliminating the foreign genome, the nuclease
and helicase activities of Cas3 also drive the production of spacer substrates
(Figure 1.2.3) 45. Further, in the absence of a proper PAM, Cascade can still bind
the target and recruit Cas3 in a manner dependent on Cas1-Cas2 67. These
distinct outcomes arise from alternative conformations adopted by Cascade, in
particular the Cse1 subunit, upon binding of either a perfect target or a mutated
target 67-70. In this context, the nuclease domain of Cas3 is inactive and it is
believed that its helicase activity is used to translocate the Cas1-Cas2 complex
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along the nearby DNA and drive primed spacer acquisition by the integrase
complex (Figure 1.2.4) 65,67.

Figure 1.2.3. Primed spacer acquisition against a perfect target.
The CRISPR RNA (crRNA)-guided CRISPR-associated complex for antiviral
defence (Cascade) binds to a foreign target in a PAM-dependent manner, and it
subsequently recruits the nuclease Cas3, which results in the generation of
suitable substrates for spacer acquisition.

Figure 1.2.4. Primed spacer acquisition against a mutated target.
Imperfect target recognition by Cascade results in an altered conformation of the
Cse1 subunit. This leads to the recruitment of a nuclease-inactive Cas3 in a
Cas1–Cas2-dependent manner, which mediates primed spacer acquisition.
14

How these two outcomes relate to one another, and how they are decided
between, remains unresolved. One possibility is that there are two distinct
pathways, namely primed spacer acquisition and interference-driven spacer
acquisition, where there is a threshold for the amount of mutations tolerated to
either license an interference or priming response. In this case, both responses
can result in elevated rates of spacer acquisition, though a significantly higher
boost in the case of interference-driven spacer acquisition 65,71,72. Alternatively, it
is possible that the CRISPR machinery does not make such strict distinctions
and rather displays a continuum of activities, ranging from interference to
priming. In this case, it has been suggested that a single mechanism could
explain this range of activities 73.
Primed spacer acquisition allows organisms to defend themselves against
rapidly evolving phage populations, like phages that evade CRISPR-Cas
immunity through the introduction of target mutations or related phages with
conserved but not identical targets64,74,75. Priming can also serve as a
mechanism to bias spacer acquisition activity to foreign DNA substrates that
harbor the priming target; i.e., using the molecular memories stored in the
CRISPR array to differentiate self vs. foreign DNA74. However, the increased rate
of spacer acquisition resulting from priming poses a dilemma for the host cell: the
more spacers a CRISPR system acquires, the more likely it is that a spacer with
a partial match to the host chromosome is incorporated, which would elicit
primed spacer acquisition from the host genome, resulting in autoimunity72. How
CRISPR systems balance these costs and benefits remains to be addressed.
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Whether priming occurs in other CRISPR Types also remains to be determined.
Similarly to the interaction between Cascade and Cas3 during priming, Cas9 has
been shown to interact with the Cas1-Cas2 integrase48, an observation that
opens up the possibility of priming in the Type II CRISPR-Cas immune response.
For Type III systems, on the other hand, the presence of mismatches between
the crRNA and the target sequence does not abrogate immunity57, and therefore
it seems unlikely that primed spacer acquisition can occur as it happens for Type
I systems.
1.5 THE ORIGIN OF SPACER SEQUENCES
CRISPR arrays give unique insight into the genetic material encountered
and selected against during the course of prokaryotic evolution. As a molecular
fossil record of past invasions, we can infer not only the genomes that a given
organism encountered but also in what order. Thus, there has been significant
interest in analyzing the origin of spacer sequences. Of the spacers that can be
mapped to sequenced genomes, 80-90% of spacers map to phage genomes
(Figure 1.3.1). The remainder of mapped spacers match genes associated with
mobile genetic elements. Surprisingly, though, a vast majority of spacer
sequences (>90%) originate from unknown sources, comprising the CRISPR
“dark matter” (Figure 1.3.1)76.

16

Figure 1.3.1. Origin of spacer sequences.
From bioinformatic analysis of CRISPR arrays in sequenced bacterial genomes,
the majority of spacers are of unknown origin. But of the fraction of spacers that
can be mapped, the majority of spacers map to phage genomes, though spacers
matching plasmids, transposons, and other mobile genetic elements can be
identified.
For these mysterious spacer sequences, perhaps the most parsimonious
explanation is that sequence databases are missing a vast diversity of phage and
MGE sequences. Indeed, sequence analysis has determined that many of these
unmapped spacer sequences share similar properties with the mapped spacer
sequences, suggesting that they would map to uncharacterized classes of
phages and mobile genetic elements77. These dark matter spacers have also
been found for a large majority of RT-Cas1-derived spacers, suggesting a
diversity of RNA phages and RNA MGEs that remain to be discovered as well78.
It is also a possibility that these spacer sequences foreshadow the discovery of
unexpected sources of nucleic acids.
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1.6 CONCLUSIONS AND OUTLOOK
More than ten years after the discovery of CRISPR’s function as a form of
prokaryotic adaptive immunity, we are fast approaching a comprehensive
understanding of the molecular mechanisms underlying spacer acquisition.
Through complementary studies utilizing genetic, biochemical and structural
approaches, we now have key insights into several major steps of this process,
from the selection of spacers from foreign genomes to the cleavage-ligation
reactions of new spacers into the first repeat of the CRISPR array. However,
gaps in our knowledge exist, particularly at the boundaries of protospacer
capture and spacer integration. For instance, while it has been demonstrated that
RecBCD and AddAB are involved in the generation of substrates for spacer
acquisition, the mechanism of this process is largely unsolved. Further, what kind
of processing protospacers undergo and how spacer size is regulated remain
understudied. It is possible that relatively uncharacterized accessory proteins
(like Cas4 and Csn2) that are associated with spacer acquisition modules could
play a role in these processes 79. The development of new in vivo and in vitro
experimental systems will be key to gaining insight into these processes. Indeed,
one such study has already suggested a role for Cas4 in PAM-dependent
protospacer processing 33.
More broadly, it will be interesting to learn how spacer acquisition affects
other aspects of prokaryotic life. From a cell biological perspective, it will be
valuable to learn more about the interplay between CRISPR spacer acquisition
and other host-encoded genes or pathways, like other phage defense
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mechanisms. From an ecological standpoint, the extent to which spacer
acquisition occurs in different environmental contexts remains to be explored.
Finally, metagenomic studies combined with establishment of new in vivo
systems will be instrumental in understanding how spacer acquisition and
CRISPR immunity influence the evolution of natural prokaryotic populations in
physiologically and ecologically relevant contexts.
The spacer acquisition machinery has begun to be repurposed for
technological applications. Rather than being used for directed genome editing
like Cas9, the Cas1-Cas2 machinery has been repurposed as a synthetic
molecular recorder80. This could be used for storing digital information in
genomes of bacterial populations81. Additionally, an alternative technique has
been developed for recording environmental signals encountered by bacterial
populations82. However, there are currently several factors that limit the utility and
function of these techniques. Most notably, the low frequency of spacer
acquisition events makes it impossible to have reliable recording within single
cells, therefore the current technologies rely on deep sequencing of large
populations to detect spacer acquisition. It is possible that tools like hyper-Cas9,
a hyperactive spacer acquisition mutant50, could accelerate both basic and
technological research in the spacer acquisition field.
The storage of information is a fundamental aspect of all biological
systems. CRISPR loci constitute a unique form of biological memory, serving to
provide heritable and adaptive immunity to prokaryotes. Future research on the
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biology of CRISPR and spacer acquisition is sure to illuminate our understanding
of biological memory, prokaryotic evolution, and host-pathogen interactions.
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CHAPTER 2: CRISPR SYSTEMS OPTIMIZE THEIR IMMUNE RESPONSE BY
SPECIFYING THE SITE OF SPACER INTEGRATION
2.1 INTRODUCTION
Prokaryotes are faced with the perpetual threat of invasion by foreign
nucleic acids through phage infection and horizontal gene transfer. Clustered
regularly interspaced short palindromic repeats (CRISPR) loci and CRISPRassociated (Cas) proteins comprise a heritable and adaptive immune system that
protects bacteria and archaea from phage2 and plasmid3 infections.
Immunological memories of these infections are stored in the CRISPR array as
short spacer sequences that intercalate between repeats and specify the targets
of CRISPR-Cas immunity. Upon infection, new spacer sequences matching the
genome of the invading DNA are added to the 5’ end of the CRISPR array2.
Therefore the CRISPR locus constitutes a molecular fossil record of infections in
which the first spacer matches the most recent foreign threat, whereas
downstream spacers correspond to older infections. The CRISPR array of
repeats and spacers is first transcribed as a long precursor that is processed at
the repeat sequences to generate small, mature, CRISPR RNAs (crRNAs)21,83,84.
These associate with and direct RNA-guided Cas nucleases to their targets,
known as protospacers, in the genome of the invader59,85-87. Cleavage of the viral
or plasmid target DNA prevents infection3,88.
Based on the cas gene content, CRISPR-Cas systems are classified into
six types (I-VI) and 19 subtypes89,90. The polarity of spacer incorporation, i.e. the
addition of new spacers in the first position of the CRISPR array, is a feature of
all CRISPR-Cas types studied so far. At the molecular level, the process of
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spacer acquisition has been mostly studied using the type I-E system from
Escherichia coli MG165518,74. The Cas1-Cas2 complex from E. coli serves as an
integrase, catalyzing a nucleophilic attack by the incoming spacer at the leaderproximal repeat9,15,16. During this concerted cleavage-ligation reaction, the spacer
is added to the array and the repeat is duplicated simultaneously. The integration
host factor (IHF) protein directs the addition of spacers into the first position of
the CRISPR array32. IHF is a histone-like bacterial protein conserved in Gramnegative organisms that binds an AT-rich region immediately upstream of the
type I-E CRISPR locus, known as the leader sequence91, creating the proper
DNA topology for Cas1-Cas2-mediated spacer integration at the first repeat.
Type II-A CRISPR-Cas systems also display a stringently polarized spacer
acquisition process2,48. However, most of these systems are present in Grampositive bacteria, which lack IHF homologs. In these systems the leader
sequence is also important for spacer acquisition35, however how the polarity of
this process is achieved is not clear. More importantly, the physiological
significance of polarized spacer acquisition, a fundamental feature of CRISPRCas immunity, has not been explored in any CRISPR type.
Here we studied these fundamental problems of spacer acquisition in the
type II-A CRISPR-Cas system of Streptococcus pyogenes SF370. Consistent
with previous studies, we found that deletions of the array-proximal region of the
leader abolish spacer integration at the leader-end of the CRISPR array.
However, these deletions do not abolish all spacer acquisition activity. Instead,
leader mutations result in the erroneous integration of new spacers into the
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middle of the array, a phenomenon we term ectopic spacer integration. Further
interrogation revealed that a short and conserved sequence at the 3’ end of the
leader dictates the site of spacer integration. By uncoupling the requirement for
the leader during spacer acquisition from its role in positioning spacer integration,
we were able to investigate the physiological significance of spacer order within
the CRISPR array. We determined that wild-type, polarized, spacer integration
provides a fitness advantage over ectopic spacer acquisition due to higher levels
of host protection provided by spacers in the leader end of the array. This
increased level of immunity is particularly critical during high titers of phage, like
those that occur during CRISPR immunization. Our results demonstrate that
polarized spacer acquisition ensures robust immunity against the latest invader,
and thereby the most immediate threat to the host.
2.2 RESULTS
Deletions within the leader sequence result in ectopic spacer integration.
The type II-A CRISPR system of S. pyogenes SF370 contains four cas
genes, a tracrRNA gene, and six spacers (spc1-6) in the CRISPR array21 (Fig.
2.1.1-A). Immediately upstream of the first repeat there is a 102 bp, AT-rich
sequence known as the leader91. We previously studied the roles of the different
cas genes in spacer acquisition by cloning this CRISPR-Cas system on the
pC194 staphylococcal plasmid and using Staphylococcus aureus RN4220, a
genetically tractable Gram-positive organism without an endogenous CRISPRCas locus, as the host92. Here we used this experimental set up to investigate the
function of the leader sequence. We created three strains containing different
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deletions of 25, 15 or 5 bp at the 3’ end of the leader sequence (Fig. 2.1.1-B).
Cultures of these mutant strains as well as a wild-type control were infected with
the staphylococcal lytic phage ΦNM4γ448 during exponential growth, at a
multiplicity of infection (MOI) of 1 virus per bacterium. After 24 hours, DNA was
isolated from the surviving cells in each culture and used for PCR analysis of the
CRISPR locus with primers that amplify the leader-end and thus detect the
acquisition of new spacers in the first position of the CRISPR array48 (Fig. 2.1.1A, blue arrows). All three deletions prevented any detectable insertion of new
spacers in this position (Fig. 2.1.1-C). This is in agreement with the results
obtained with the type II-A CRISPR1 locus of Streptococcus thermophilus
DGCC771035. All of the leader deletion strains tested gave rise to bacteriophageresistant mutants, however, which suggested that the CRISPR-Cas immune
response could still be functional. We hypothesized that spacer acquisition could
occur in other positions of the CRISPR array and therefore used a different set of
primers to detect the incorporation of new spacers in any position (Fig. 2.1.1-A,
green arrows). Surprisingly we were able to observe bona fide spacer acquisition
events in the middle of the CRISPR array (Fig. 2.1.1-C). Upon sequencing of
many of these PCR products we determined that, in all three leader deletion
mutants, the majority of spacer integration events occurred at the fifth repeat,
positioning the new spacer between spc4 and spc5 (Fig. 2.1.1-D). We term this
phenomenon, in which new spacers are added into the middle of the array,
“ectopic” spacer integration. These experiments provide direct, in vivo evidence
that the leader is involved in specifying the site of spacer integration.
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Figure 2.1.1. Deletions within the Leader Sequence Result in Ectopic
Spacer Integration
(A) Type II-A CRISPR locus from Streptococcus pyogenes SF370. A 102 bp
leader sequence separates the cas genes from the CRISPR array, which
contains seven repeats (R1–7) flanking six spacers (spc1-6). Blue and red
arrows indicate primers used to detect spacer integration at the leader-end
(polarized) or at the middle of the array (ectopic), respectively.
(B) Deletions of the leader sequence analyzed in this study.
(C) PCR-based detection of polarized or ectopic spacer integration using the
primers described in (A). DNA for PCR was extracted from colonies obtained
from cultures incubated with (+) or without (−) phage ΦNM4γ4. PCR products
were separated by agarose gel electrophoresis and stained with ethidium
bromide. A gel image representative of many PCRs is shown. The size of the
PCR product reflects the presence (a, “adapted”) or absence (u, “unadapted”) of
integration of new spacers.
(D) Position of spacer integration events (marked by the black arrows) after
Sanger sequencing of PCR products obtained in (C) for cells infected with phage
carrying different leader sequence deletions. Numbers in table represent totals
from three replicates.
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A leader-anchoring sequence specifies the site of integration for new spacers.
To investigate the leader sequences that specify the site of integration of
new spacers in more detail, we introduced A-C and G-T transversion mutations
in the 10 bp at the 3’-end of the leader. We tested two mutants, one with
mutations in the -5 to -1 region of the leader and one with mutations in the -10 to
-6 region (Fig. 2.2.1-A). PCR analysis after phage infection with each set of
primers used in Figure 1 showed that only the -5 to -1 leader mutant resulted in
ectopic spacer integration (Fig. 2.2.1-B). We have therefore termed this region of
the leader the “leader-anchoring sequence,” or LAS. This sequence, especially
the 3’-end GAG, is highly conserved in related type II-A CRISPR systems93 (Fig.
2.2.2-A). To precisely determine the effect of the LAS on the position of spacer
integration within the CRISPR locus, we performed next-generation sequencing
of the PCR products containing the full array obtained after infection of wild-type
and LAS mutant cultures. We found that while wild-type cells displayed polarized
spacer integration almost exclusively (>99.999% of new spacers were integrated
into the first repeat, Fig. 2.2.1-C), LAS mutant bacteria acquired new spacers at
different positions in the array, with only ~ 0.65 % of the integration events
occurring at the first repeat and more than 99% at the fifth repeat, positioning the
new spacer between spc4 and spc5 (Fig. 2.2.1-C).
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Figure 2.2.1. A Sequence within the Leader Specifies the Site of Spacer
Integration
(A) Mutations were introduced at the 3′ end of the leader to define the leaderanchoring sequence (LAS). (B) Strains containing the leader mutations described
in (A) were infected with phage ΦNM4γ4 and analyzed by PCR for polarized and
ectopic spacer integration. (C) Analysis of the site of spacer integration using
next-generation sequencing. Liquid cultures harboring a wild-type or mutant LAS
were infected at an MOI of 1, and the DNA isolated from surviving cells at the
end of infection was used for PCR amplification of the entire array. The expanded
PCR amplicons were purified from the gel and used for MiSeq next-generation
sequencing. Bars show the number of normalized reads for the integration of new
spacers in each possible position of the CRISPR array (marked by the black
arrows). Mean ± SEM of three replicates are reported. Percentage of spacer
integration events is indicated above each bar.
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Figure 2.2.2. The leader anchoring sequence is conserved in related Type
II-A CRISPR systems.
(A) Alignment of leader sequences upstream of the first repeat of type II-A
CRISPR-Cas systems present in different bacteria. Red indicates strong
conservation, yellow indicates average conservation, green indicates poor
conservation. (B) Alignment of the 30 nucleotide leader sequence upstream of
the first repeat of the S. pyogenes CRISPR locus and the spc4 sequence. (C)
Spacer integration in cells harboring a CRISPR locus in which the sequences of
spc2 and spc4 were swapped, downstream of a wild-type LAS. (D) Spacer
integration in cells harboring a CRISPR locus in which the sequences of spc2
and spc4 were swapped, downstream of a mutant LAS. (E) Spacer integration in
cells harboring a CRISPR locus in which the sequences of repeat #5 and spc4
were deleted, downstream of a mutant LAS.
We wondered whether the sequence of spc4 could work as a “pseudoLAS” upstream of the fifth repeat that would direct the integration of new spacers
in the absence of the wild-type LAS upstream of the first repeat. Comparison of
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the LAS and spc4 sequences indicated that there is very little homology between
them (Fig. 2.2.2-B). However, it is possible that different sequences could serve
as anchors for spacer integration. To test this, we switched the positions of spc2
and spc4 and determined the location of newly acquired spacers. As expected,
switching the spacers did not affect polarized acquisition in the strain harboring
the wild-type LAS (Fig. 2.2.2-C). However, all of the LAS-mutant, phage-resistant
colonies tested contained the new spacer integrated in the third repeat, i.e.
immediately downstream from the new location of spc4 in this strain (Fig. 2.2.2D). In addition, the combination of the LAS mutation and the deletion of spc4
prevented the detection of spacer integration (Fig. 2.2.2-E). These results
suggests that in the absence of a proper LAS, other sequences within the type II
CRISPR array (spc4 in the case of the S. pyogenes CRISPR-Cas system) can
anchor spacer integration. Altogether our experiments show that short
sequences immediately upstream of repeats are able to specify the site of spacer
integration. In particular a short conserved sequence within the CRISPR leader
immediately upstream of the first repeat, here named the LAS, specifies the
acquisition of new spacers in the first position of the array with high fidelity.
The LAS provides a competitive advantage during spacer acquisition.
Our experiments with LAS mutant cells showed that the CRISPR-Cas
immune response does not absolutely require the addition of new spacers in the
first position. In spite of this, all CRISPR-Cas systems studied so far display an
invariable specificity for spacer integration in this position. We wondered if
polarized spacer acquisition provided an advantage versus ectopic acquisition.

29

To test this we carried out a series of competition analyses between strains that
acquire spacers in different positions within the CRISPR array. First we
performed a pairwise competition assay between strains harboring wild-type or
mutant LAS. Each of the two naïve strains were grown to exponential phase and
mixed in a 1:1 ratio. One aliquot of the mixed culture was uninfected as a control,
while another was infected with phage ΦNM4γ4 at an MOI of 1. The cultures
were grown for 24 hours and then streaked onto agar plates. DNA from individual
colonies (originating from cells that survived phage infection) was used for PCR
and Sanger sequencing to determine the population composition after the
experiment (16 colonies were analyzed per replicate; 48 colonies total), Fig.
2.3.1-A). The control showed a 1:1 ratio of wild-type to LAS mutant cells in the
absence of phage infection, indicating that there is no intrinsic selective
advantage for any of the strains (16 colonies were analyzed per replicate; 48
colonies total). In contrast, in the presence of phage only the strain harboring the
wild-type leader was able to generate resistant colonies, suggesting a strong
fitness defect for the LAS mutant cells. As expected, all the colonies contained
new spacers in the first position of the CRISPR array (Fig. 2.3.2-A). This fitness
defect was also observed during monoculture phage challenges, where the
survival of cells is measured as the optical density of the culture after addition of
phage (Fig. 2.3.1-B). In this experiment naïve cells succumb to viral infection and
the optical density decreases dramatically. However, cultures can regain growth
upon acquisition of new spacer sequences that direct phage destruction. While
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cells harboring a wild-type leader sequence restart growing at ~16 hours, LAS
mutants take ~25 hours to regrow.

Figure 2.3.1. The LAS Confers a Fitness Benefit during CRISPR-Cas
Immunity
(A) Analysis of culture composition following direct competition between strains
harboring the wild-type or mutant LAS. Strains were mixed in a 1:1 ratio and
infected with phage ΦNM4γ4 at an MOI of 1. Once the infection completed, the
cultures were streaked onto a plate and colonies were picked to determine their
LAS by Sanger sequencing (n = 16 per condition per replicate, 96 colonies tested
in total). Mean + SEM of three replicates are reported. L.d, limit of detection.
(B) Growth of cultures infected with phage ΦNM4γ4 followed by the
measurement of optical density at 600 nm (OD ). Cells containing a wild-type or
600

mutant LAS were infected, and their OD was followed over time. While most
600

cells die after infection, a small fraction can acquire new spacers and resume
growth after viral clearance through CRISPR-Cas immunity. Mean ± SEM (gray
dotted line) of three replicates are reported.

31

Figure 2.3.2. Deletions of repeat-spacer units within the CRISPR locus shift
ectopically integrated spacers to the leader-end of the array.
(A) DNA from mixed cultures incubated with (+) or without (-) phage ΦNM4γ4
(from Fig. 3A, which contains the average of the three biological replicates for
each condition reported here) was extracted 24 hours post-infection and used as
template for PCRbased detection of polarized or ectopic spacer integration as in
Fig. 1A. (B) DNA from cells harboring a mutant LAS that recovered after phage
infection (from Fig. 2C) was extracted and used as template for PCR to detect
expansion of the CRISPR array. In addition to PCR products corresponding to
expanded, or adapted (a), and unadapted (u) CRISPR loci, a third PCR product
(d), smaller than the other two, was observed. (C) Next-generation sequencing of
the DNA rendered sequences corresponding to the smaller band in which the first
four repeat-spacer units were deleted and the fifth, newly acquired spacer was
repositioned as the first spacer.

Interestingly, when preparing the samples for next-generation sequencing
(Fig. 2.2.1-C), we noticed an additional PCR product from the LAS mutant
sample, smaller than both the naïve and adapted CRISPR arrays present in both
populations (Fig. 2.3.2-B). Sequencing of these PCR products revealed the
presence of CRISPR loci that had lost the first four repeat-spacer units to
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relocate the new spacer in the first position (Fig. 2.3.2-C). This result shows that,
in the event of ectopic adaptation, there is selective pressure to reposition new
spacers to the leader-end of the array. Altogether these experiments
demonstrate that, by enabling the acquisition of new spacers in the first position
of the CRISPR array, the LAS confers a selective advantage during the CRISPRCas immune response.
Spacers in the first position of the CRISPR array provide a more robust immune
response.
There are at least two possible explanations for the fitness advantage of
cells harboring a wild-type LAS observed in Figure 3. One scenario is that spc4
has poor LAS properties and spacer integration at position 5 (in the LAS mutant)
is less efficient than at the first position (in the wild-type CRISPR locus). Another
possibility is that spacers integrated into repeat 5 provide a weaker CRISPR
immune response and take more time to clear the virus and regrow. To explore
the first scenario, we replaced spc4 with a 30 bp fragment of the leader
containing the LAS (Fig. 2.4.1-A). In this way the LAS is present upstream of
both the first and fifth repeats, and there is an optimal LAS for the acquisition of
spacers in the first or fifth position of the CRISPR array. This set up allowed us to
perform an “intracellular competition experiment” in which integration at repeat 1
(the wild-type position) and repeat 5 (the ectopic position) should have similar
rates. We first corroborated that, in the absence of a wild-type in the LAS
upstream of the first repeat, the replacement of spc4 for the LAS resulted in the
exclusive acquisition of new spacers in position 5 (Fig. 2.4.2-A). This also
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demonstrates that the LAS positively directs spacer acquisition, and therefore
that the particular LAS mutations that we introduced are not inhibitory for spacer
incorporation. Next, we infected cells harboring a duplicated LAS and analyzed
the surviving colonies (Fig. 2.4.1-A). Spacer acquisition events were detectable
at both leader-repeat junctions, but spacers integrated into the first repeat were
highly enriched after phage selection (in fact, ectopic spacer integration was
observed only in 1 of 6 replicates). These data show that polarized spacer
acquisition is favored over ectopic spacer acquisition even when both integration
events are mediated by the same, wild-type, LAS. Although it is still possible that
upstream leader sequences not included in the 30 bp LAS spacer have a minimal
positive effect on the efficiency of spacer acquisition, this result suggests that the
selective advantage of the wild-type CRIPSR-Cas system is not due to a low rate
of spacer incorporation in LAS mutant cells, but rather reflects a difference in the
level of immunity provided from different positions within the CRISPR array.
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Figure 2.4.1. Leader-End Spacers Provide More Robust Immunity than
Spacers in the Middle of the CRISPR Array
(A) Analysis of the site of spacer integration in a strain harboring two copies
of the LAS, upstream of the first and fifth repeat. A culture was infected with
ΦNM4γ4 at an MOI of 1. The CRISPR array from surviving cells was amplified
and subjected to Sanger sequencing to determine the position of integration
(marked by the black arrows) of new spacers. Mean + SEM of six replicates are
reported.
(B) Two strains were engineered to test the levels of CRISPR-Cas immunity
provided by the same spacer sequence located in the first (Position 1 strain) or
fifth (Position 5 strain) position. In addition, the cas1 gene was mutated to
prevent the acquisition of new spacers.
(C) Growth of Position 1 and Position 5 cultures infected with phage ΦNM4γ4 at
MOI 5 or 50 followed by the measurement of optical density at 600 nm (OD ).
600

Mean of three replicates is reported.
(D) Simulation of CRISPR immunization with Position 1 and Position 5 strains.
Position 1 or Position 5 cells were diluted with cells lacking CRISPR-Cas in a
1:10,000 ratio and infected with phage ΦNM4γ4 at an MOI of 1. Cell growth that
results from CRISPR-Cas immunity was monitored by optical density
measurements at 600 nm (OD ) for 24 hr. Cells lacking a CRISPR-Cas system
600

were used as control. Mean ± SEM (gray dotted line) of three replicates is
reported.
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Figure 2.4.2. Spacer sequences in position 1 provide better CRISPRCas
immunity than spacers in position 5.
(A) Spacer acquisition after phage infection of cells containing a mutant LAS
upstream the first repeat and a wild-type LAS instead of spc4. Surviving cells
were plated and DNA from colonies was extracted for PCR. Sanger sequence of
PCR products was used to determine the position of integration (marked by the
black arrows) of the new spacer. Mean ± SEM of three replicates are reported.
(B) Efficiency of plaquing (EOP) of the phage ΦNM4γ4 on plates containing cells
with a targeting spacer in position 1 or 5. To calculate the EOP, the number of
plaques formed on each of these strains is divided the number of plaques
obtained using cells without CRISPR-Cas immunity that support full viral
propagation. EOP = 10-9 is the lower limit of detection of the assay. Mean ± SEM
of three replicates are reported. (C) Picture of the plates used for panel (B), in
which 10-fold serial dilution of the phage ΦNM4γ4 were spotted on Position 1 or
Position 5 cells. The inhibition of growth zone observed in the 10-3 dilution is
marked. (D) Assay that simulates CRISPR-Cas immunization. Cells already
immunized (with a spacer targeting the phage ΦNM4γ4) are mixed with an
excess of non-immune cells at different proportions and infected with phage. The
time that it takes for each mixed culture to regain growth correlates with the
amount of immunized cells in the sample. Mean ± SEM (gray dotted line) of three
replicates is reported. (E) RNA-seq of Position 1 and Position 5 cells showing the
read count (normalized to total reads) for the crRNA derived from the same
spacer sequence integrated in each of these positions.
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We examined the second possibility by directly comparing the levels of
CRISPR immunity provided by polarized and ectopic spacer acquisition. We
engineered two CRISPR-Cas systems containing the same spacer sequence
(GTGTTCTCTTCAATCCATTCATCTATTGCT) in two different positions within
the array (Fig. 2.4.1-B), one mimicking polarized spacer integration (“Position 1”)
and the other mimicking ectopic spacer integration (“Position 5”). To prevent
additional immunization events, spacer integration was abrogated in both strains
by the introduction of an inactivating mutation (E220A) in the Cas1 integrase48,94.
Both strains were grown to exponential phase and infected with phage ΦNM4γ4
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at two MOIs, 5 and 50, and growth was monitored by measuring the optical
density of the cultures (Fig. 2.4.1-C). Position 1 and Position 5 strains exhibited
comparable levels of immunity at an MOI of 5. In contrast, at an MOI of 50, the
Position 5 strain showed a severe growth defect. A similar result was obtained
when phage propagation was measured on plates containing Position 1 or
Position 5 cells, seeded with 10-fold serial dilutions of the phage ΦNM4γ4 stock.
Whereas the number of plaques originating from phage escapers (usually
harboring mutations in the target sequence that makes them refractory to
CRISPR-Cas immunity 53) were similar for both strains (Fig. 2.4.2-B), Position 5
plates showed an inhibition of growth zone (most notable at the 10-3 dilution, Fig.
2.4.2-C), suggestive of some level of phage propagation due to a poor CRISPRCas defense. Altogether these experiments demonstrate that while spacers in
any location of the array confer some level of immunity to the host, positioning
the immunity-conferring spacer at the leader-end of the array enables a more
robust immunity at higher titers of phage.
CRISPR-Cas immunization is a rare event, calculated to happen only in 1
in 107 cells of the infected population in our experimental set up48. As a
consequence of this, most cells in the culture succumb to viral infection, creating
very high titers of phage. We estimated that the small fraction of cells that is able
to acquire a new spacer against the phage face an extremely high MOI (on the
order of 10,000). Given the results obtained in Figure 2.3.1-A, we speculated that
the position of the targeting spacer in the CRISPR array could be critical for the
CRISPR immune response under these extreme phage stresses. To test this we

39

developed an assay that simulates the CRISPR immunization process in which a
small proportion of CRISPR-immune cells (already harboring a phage-targeting
spacer sequence in either position 1 or position 5) is mixed with a majority of
non-CRISPR cells that enables exponential phage propagation. In this assay, the
time at which the culture resumes growth after viral infection is delayed
proportionately to the fraction of CRISPR-immune cells (Fig. 2.4.2-C). When the
Position 1 CRISPR-immune strain is tested, growth resumes at ~15 hours (Fig.
2.4.1-D). In stark contrast, when the Position 5 CRISPR-immune strain is used
growth resumes at ~20 hours. This pattern mirrors the growth curves produced
during CRISPR immunization of wild-type and LAS mutant cultures (Fig. 2.3.1-B).
Together, these results demonstrate that cells in which spacers are integrated
ectopically suffer a severe growth defect due to compromised immunity.
2.3 DISCUSSION
A hallmark feature of CRISPR-Cas systems is the integration of short viral
spacer sequences into the 5’-end of the CRISPR locus2. However, the
physiological significance of this highly polarized process has remained
unknown. Here we studied this problem in the type II-A CRISPR-Cas system of
S. pyogenes. We found that a short sequence immediately upstream of the first
CRISPR repeat, which we called the leader-anchoring sequence or LAS, is
required for the exclusive insertion of spacer sequences in the first position of the
CRISPR array. Mutations in the LAS result in the integration of new spacers in
the middle of the array, a phenomenon we called ectopic spacer integration. The
phenotype of the LAS mutant allowed us to determine the importance of ordered
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spacer addition during the CRISPR immune response against phage infection.
We found that polarized spacer integration bestows the host with a competitive
advantage by positioning the new spacer in the first position of the array, where
spacers provide more robust CRISPR-Cas immunity. Since the first spacer
derives from the most recent invader, polarized spacer acquisition allows
CRISPR-Cas systems to prioritize immunity against the most immediate threat to
the host.
Given that Cas9 acts as a single-turnover enzyme27, each crRNA
molecule that directs the cleavage of one invading phage cannot be re-used to
cleave a second viral genome. Therefore, the abundance of a targeting crRNA
could be critical during CRISPR immunization, when cells are challenged by an
extremely high number of phages. This is because upon infection of a naïve
bacterial population, the viral titers rise to extraordinary levels due to the initially
unconstrained transmission of the virus. In this exceptional condition in which a
few newly-immunized cells are infected by thousands of phages at the same
time, the abundance of the crRNA guide produced from the new spacer could be
decisive for the success of the CRISPR-Cas immune response. Higher
abundance of leader-end crRNAs has been observed in many CRISPR-Cas
systems21-25. Importantly for our study, the S. pyogenes type II-A CRISPR-Cas
system produces higher levels of spc1 crRNA than the other crRNAs derived
from downstream spacers21. Further supporting this scenario, we found that the
levels of the ΦNM4γ4-targeting crRNA produced from Position 1 is ~2-fold higher
than when it originates from Position 5 during exponential growth (Fig. 2.4.2-E).
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We believe that it is conceivable that the same spacer sequence integrated in the
first or a more downstream position of the CRISPR array could produce different
levels of mature crRNA due to asymmetric transcription and/or differential
processing of the crRNA precursor. The molecular mechanisms that lead to the
uneven distribution of crRNAs, and how small differences in crRNA abundance
affect the CRISPR immune response, will require further investigation, in type II
and other CRISPR types.
While the LAS is critical for the integration of new spacers into the first
repeat, we have found that the spc4 sequence can also specify the addition of
spacers into the repeat that follows it. In addition, the mutations inserted in the
LAS (-1 to -5) do not completely abrogate the integration of spacers in the first
position of the CRISPR array (Fig. 2.2.1-C). These results suggest that other
sequences or sequence motifs can perform the LAS function. Moreover, it is
possible that upstream sequences within the leader could contribute to spacer
integration, though such sequences were not detectable in a related Type II-A
CRISPR system (Wei et al.). We propose that the Cas1-Cas2 integrase complex
samples the nucleotides immediately upstream from the repeat and that the wildtype LAS provides the optimal sequence for anchoring the complex, biasing its
activity toward the leader-end of the array. In the type I CRISPR-Cas system,
binding of IHF to the leader creates the required DNA topology for spacer
integration at the 5’-end of the array. Given the absence of IHF homologs in
Gram-positive bacteria (including the host used in our studies, S. aureus) it is
possible that there are other factors that perform a similar function for type II
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CRISPR-Cas systems95. Alternatively, the type II Cas1-Cas2 complex could be
sufficient to catalyze polarized spacer integration without a requirement for
additional host factors31. Additional work employing biochemical and structural
techniques will address these questions.
The prioritization of the CRISPR-Cas immune response against the most
recent invader has been proposed as a bet-hedging strategy20. This is analogous
to the mammalian adaptive immune response, where effector T-cell populations
and antibody titers against a virus are highest immediately post-immunization
and gradually decrease over time96. By devoting more resources to defending the
host against the most recent infection, immune systems provide robust protection
against the infectious agents that are most likely to be present at high titers. This
is an efficient way to conserve resources while still providing robust immunity
against the most threatening attackers. For CRISPR-Cas systems, the benefit of
deprioritizing immunity against past invaders would be two-fold. First, during
infection of a population that has been immunized in the past, i.e. harboring the
invader-matching spacer in the middle of the array, transmission of the reinfecting virus will be immediately contained and viral titers will remain low. In this
situation the CRISPR-Cas immune response does not need to be at peak levels
to efficiently protect the population, as shown in Figure 4C in which a spacer in
position 5 provides full immunity in conditions of low MOI. Second, it has been
reported that phage mutations in target sequences are highly abundant in viral
populations and are selected for their ability to enable the escape from CRISPRCas immunity53,97. Therefore there is a high probability that spacers in the middle
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of the array would not be able to provide immunity against re-infecting, mutated
phages. In this scenario, maintaining full expression of these spacers would also
be wasteful. Interestingly, in a scenario of re-infection by high titers of a nonmutated virus, an old spacer sequence can regain full potency through its
repositioning as the first spacer sequence (similar to our results of Figure 2.3.2).
Recombination and deletion within the CRISPR array have been extensively
described in natural populations97,98 and could represent a functional, rather than
accidental, feature of CRISPR-Cas loci. Our results ascribe a physiological role
to the establishment and preservation of the timeline of infection that is a
hallmark of CRISPR-Cas immune systems and further our understanding of the
selective pressures that guide the evolution of CRISPR systems.
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CHAPTER 3: CRISPR SYSTEMS MODULATE LIFESPAN OF
IMMUNOLOGICAL MEMORIES BY TUNING RATES OF SPACER
ACQUISITION

3.1 INTRODUCTION
Bacteria are under constant evolutionary pressure from phage threats.
CRISPR-Cas systems confer adaptive and heritable immunity to bacteria by
incorporating short segments of viral DNA, termed spacers, into their genome.
Spacers are intercalated between semi-palindromic, direct repeats in host loci
known as CRISPR arrays. Spacers, once transcribed into CRISPR RNAs
(crRNAs), serve as immunological memories that guide effector nucleases to
seek and destroy foreign cognate nucleic acids, thereby neutralizing viral threats
during the interference stage of CRISPR immunity. CRISPR-associated (cas)
genes encode the protein components of the immune system and are the basis
by which CRISPR systems are categorized. To date, there are six types and over
twenty subtypes of CRISPR systems99,100.
cas1 and cas2 are the most conserved cas genes and can be found in all
six types100. Together, they form the Cas1-Cas2 integrase, a heterohexameric
complex that mediates the spacer integration process. New spacers are added
unidirectionally to the CRISPR array and as a result, the array represents a
chronological record of past infections. The most recently acquired spacers are
found at the 5’-end of the array and the most ancestral ones are downstream at
the 3’-end of the array. The leader is a stretch of DNA that lies immediately
upstream of the CRISPR array and plays an important role in enforcing polarized
spacer integration. In Type II CRISPR systems, the Cas1-Cas2 complex makes
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sequence-specific contacts with the last five nucleotides of the leader, known as
the leader-anchoring sequence (LAS)5,19,100. This is thought to stabilize the
integrase complex and enable faster reaction kinetics for spacer integration at
the leader-end of the array5,13,14,19,100. Spacers at the leader-end of the CRISPR
array give rise to a more robust immune response relative to downstream
spacers. Thus, the chronological storage of spacers allows CRISPR systems to
prioritize resources against the most recent invader19. However, as a
consequence, addition of new spacers shifts existing spacers further downstream
within the array, thereby reducing the potency of older spacers. Furthermore, it
has been shown that an increased number of spacers within a CRISPR array
weakens the interference provided by individual spacers, likely by a dilution
effect101. How CRISPR systems balance the benefits of acquiring new spacers
with the cost of weakening existing spacers has not been explored.
We hypothesized that natural variation in spacer acquisition rates could
exist and be a means for CRISPR systems to modulate the lifespan of existing
spacers. Indeed, our lab previously demonstrated that the rate of spacer
acquisition could be boosted by artificially introducing mutations in Cas9, the
hallmark protein of Type II-A CRISPR systems50. Here, we compare the immune
responses generated by a variety of Type II-A CRISPR systems and show
significant variation in immunization rates across these systems. CRISPR
systems that acquire new spacers at a high frequency can rapidly respond to
new threats, but existing spacers quickly lose their potency. In contrast, CRISPR
systems that exhibit low-frequency spacer acquisition prioritize the immunity
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conferred by existing spacers at the cost of a slower uptake of new spacers. We
found that bacteria have overcome these tradeoffs by harboring multiple CRISPR
systems that acquire spacers at different rates. Furthermore, we have
demonstrated that these related CRISPR systems can acquire new spacers
independently of each other as a result of specific interactions between the
acquisition machinery and the leader-repeat junction. We propose a model in
which bacteria can utilize multiple CRISPR systems as a means to form both
short- and long-term immunological memories to defend against a diversity of
threats.
3.2 RESULTS
Type II-A CRISPR systems exhibit natural variation in their rates of spacer
acquisition
Natural variation is a key component of evolution and allows for selective
pressures to refine the functionality of biological phenomena102. Given that
previous work from our lab demonstrated that artificially introduced mutations in
Cas9 could alter the rate of spacer acquisition50, we sought to determine if
CRISPR systems naturally exhibit variation in their rates of spacer acquisition.
We reasoned that analysis of closely related CRISPR systems would help to
minimize confounding variables that could be introduced when comparing more
evolutionary distant systems. We started by analyzing the spacer content of a
variety of Type II-A CRISPR systems (N=80)103. Interestingly, we observed a
wide range in the number of spacers in CRISPR arrays (min: 1, max: 69, mean:
21.5; Figure 3.1.1-A). This range in the number of spacers suggested that the
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frequency of spacer addition could vary significantly across different Type II-A
CRISPR systems.

Figure 3.1.1. Type II-A CRISPR systems exhibit natural variation in their
rates of spacer acquisition.
(A) Analysis of the number of spacers in Type II-A CRISPR arrays from
previously sequenced genomes. (B) PCR analysis of CRISPR arrays at 24 hours
post infection (MOI 1 pfu/cfu). (C) Growth curves of cell cultures harboring
different CRISPR systems and infected with phage at MOI 1 pfu/cfu. (D) Analysis
of bacteriophage-insensitive mutants at 24 hours post infection in a soft-agar
phage infection assay.
To test this experimentally, we chose four Type II-A CRISPR systems
originating from streptococcal hosts: Streptococcus pyogenes SF370
(SpyCRISPR), Streptococcus mutans NN2025 (SmuCRISPR), and
Streptococcus thermophilus LMD-9 CRISPR01 (SthCRISPR01) and CRISPR03
(SthCRISPR03). We individually cloned and tested each CRISPR system in
Staphylococcus aureus RN4220 as done previously19,41,48,50. This experimental
system allowed us to compare the immune responses of CRISPR systems
originating from different organisms in a more controlled manner (i.e. infection
with the same phage, growth in identical media, same host genetic background).
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In addition, we truncated the CRISPR arrays so that each only contained a single
spacer in order to minimize spacer-specific effects. We monitored the growth of
each CRISPR-containing strain after infection with the lytic virus ФNM4γ4 48 at a
multiplicity of infection (MOI) of 1 pfu/cfu (Figure 3.1.1-B). We observed
significant variability in the time elapsed before the cells recovered from the
phage infection suggesting variability in their immune responses. Using PCRbased analysis of the CRISPR arrays 24 hours post infection, we were able to
detect spacer acquisition in all four systems with qualitative differences
consistent with the variability we observed in the growth curves (Figure 3.1.1-C).
SmuCRISPR and SthCRISPR01 exhibited multiple bands corresponding to up to
2 or 3 newly added spacers, while SpyCRISPR and SthCRISPR03 only had a
prominent band corresponding to the addition of a single new spacer. We then
tested these CRISPR systems using a soft agar spacer acquisition assay, in
which each colony originates from a single BIM (bacteriophage-insensitive
mutant). Because all liquid cultures reached peak OD600 values by approximately
22 hours post infection, we quantified phage-resistant colonies at 24 hours post
infection. Again, we observed variability (>1 log) in the rates of spacer acquisition
(Figure 3.1.1-D) and these results were consistent with our liquid phage infection
assays. To test the generalizability of these results, we performed the same
assay for each Type II-A CRISPR system using another lytic staphylococcal
phage, ФNM1γ658. We observed a similar pattern in both liquid and soft agar
phage infections (Figure 3.1.2-A-C). Notably, while no correlation was observed
in the soft agar infection with ФNM4γ4 (R2 = 0.09604; Figure 3.1.2-D), the colony
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count for the soft agar experiment with ФNM1γ6 had a strong correlation with the
number of spacers naturally found in the array of each system (R2=0.9826;
Figure 3.1.2-E). Based on these results, we conclude that Type II-A CRISPR
systems exhibit natural variation in their rates of spacer acquisition and that this
results in differentially expanded CRISPR arrays in nature.

Figure 3.1.2. Natural variation in the rates of spacer acquisition against
phage ФNM1γ6.
(A) PCR analysis of CRISPR arrays at 24 hours post infection (MOI 1 pfu/cfu).
(B) Growth curves of cell cultures harboring different CRISPR systems and
infected with phage at MOI 1 pfu/cfu. (C) Analysis of bacteriophage-insensitive
mutants at 24 hours post infection in a soft-agar phage infection assay. (D&E)
Comparison of the number of spacers found in WT array with soft-agar BIM
formation rate for (D) ФNM4γ4 and (E) ФNM1γ6.
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S. thermophilus LMD-9 utilizes two Type II-A CRISPR systems to form short- and
long-term immunological memories
Because adding new spacers and shifting existing spacers further
downstream within an array weaken their level of immunity conferred19,101, we
reasoned that CRISPR systems could regulate the potency and lifespan of
existing spacers by evolutionarily tuning their rate of spacer acquisition. High
frequency spacer acquisition is beneficial for fast responses to new challenges,
whereas low frequency spacer acquisition preserves potency of existing spacers
and retains immunity against recurring threats. Therefore, both high- and lowfrequency systems have costs and benefits, but harboring both varieties would
allow bacteria to overcome these tradeoffs. We hypothesized that this could be
the case for Streptococcus thermophilus LMD-9, which harbors two Type II-A
CRISPR systems that exhibit high- and low-frequency spacer acquisition2,35.
We developed an experimental system to study the interplay between the
two Type II-A CRISPR systems of S. thermophilus LMD-9 by introducing them
into S. aureus RN4220. Upon infection of this double CRISPR-containing strain
with ФNM4γ4, we observed regrowth of the population approximately 11 hours
post infection (Figure 3.2.1-A) and detected addition of spacers to both arrays,
with more spacer addition detectable in the CRISPR01 locus (Figure 3.2.1-B).
This was consistent with the results from a soft agar infection assay when we
challenged the strain with ФNM4γ4 and analyzed both CRISPR arrays of each
colony at 24 hours post infection. We found that 92.49% of the surviving colonies
had acquired at least one spacer in one of the CRISPR arrays and 87.45% of
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new spacers were added to CRISPR01 (Figure 3.2.1-C). These results are
consistent with what has been observed in its native host, suggesting that our
experimental system is a faithful recapitulation.

Figure 3.2.1. The two Type II-A CRISPR systems of S. thermophilus acquire
spacers at different rates when expressed in the same cell.
(A) Growth curves of cell cultures harboring different configurations of CRISPR
systems from S. thermophilus LMD-9 and infected with phage at MOI 1 pfu/cfu.
(B) PCR analysis of CRISPR arrays at 24 hours post infection (MOI 1 pfu/cfu).
(C) Analysis of spacer acquisition in cells harboring the two Type II-A CRISPR
systems of S. thermophilus at 24 hours post infection in a soft-agar phage
infection assay. (D) Deep sequencing analysis of spacer acquisition in the two
CRISPR arrays at an early time point. (E&F) Growth curves of cells harboring two
sets of overlapping spacers in the two CRISPR systems of S. thermophilus
infected by phage at different MOIs.
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To further confirm that the differences in spacer addition we observe is
due to differences in spacer acquisition activity rather than interference-related
effects, we amplified and isolated CRISPR loci at 30 minutes post infection using
a high-sensitivity detection method48. This allowed us to measure spacer
acquisition independent of interference and survival of the phage infection (lytic
cycle of ФNM4γ4 is ~45 minutes). Indeed, we observed greater rates of array
expansion in CRISPR01 relative to CRISPR03 (more abundant species
corresponding to double and triple spacer addition in CRISPR01; Figure 3.2.2-A).
Upon high-throughput sequencing and analysis of phage-targeting spacers, we
observed that the CRISPR01 locus acquired more spacers than CRISPR03 by
greater than one order of magnitude (Figure 3.2.1-D). We next tested for
differences in interference by comparing the immunity provided by two different
sets of spacers for CRISPR01 and CRISPR03. Because each Cas9 has different
protospacer adjacent motif (PAM) sequence requirements34, it is impossible to
test identical spacer sequences against the same phage, but we were able to
design two sets of spacers that share 29/30 bp of homology with overlapping
PAMs. Indeed, both sets of spacers provided similar protection at various MOIs
(Figure 3.2.1-E&F). We also tested the rate of escaper phage generation against
three different spacers for each CRISPR system and found no significant
difference between the two systems (p = 0.3745; Figure 3.2.2-B). Therefore, we
conclude that CRISPR01 and CRISPR03 acquire spacers at different rates as a
result of differences in spacer acquisition activity, rather than differences in
interference.
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Figure 3.2.2. Short- and long-term storage of immunological memories in
the Type II-A CRISPR systems of S. thermophilus.
(A) PCR analysis of spacer acquisition in the two CRISPR arrays from an early
time point phage infection visualized via tapestation. (B) Analysis of phage
escape rate against three different spacers in each CRISPR system. (C)
Schematic of CRISPR arrays used to test immunity provided by the same spacer
upon addition of four additional spacers with random sequences. (D&E) Growth
curves of cell cultures harboring a phage-targeting spacer in either an ancestral
or +4 spacers position within the (D) CRISPR01 or (E) CRISPR03 system upon
infection with phage at MOI 100 or 1 pfu/cfu, respectively. (F) Probabilistic model
predicting the number of phage infections needed to shift the current spacer 1 to
position 5 within the CRISPR array for the two CRISPR systems.
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We hypothesized the different rates of spacer acquisition observed for the
two Type II-A CRISPR systems allows S. thermophilus to form both short- and
long-term immunological memories. To support this model, we set out to
determine whether spacers in the two Type II-A CRISPR systems of
Streptococcus thermophilus lose potency upon addition of new spacers. For
each CRISPR system, we tested the same phage-targeting spacer in two
different arrays, one with the spacer as the first spacer in the array (ancestral)
and one with four additional non-targeting spacers upstream of the phagetargeting spacer (+4 spacers) (Figure 3.2.2-C). As predicted, the addition of the
four new spacers resulted in a weaker immune response for both SthCRISPR01
and SthCRISPR03 (Figure 3.2.2-D&E). Based on our calculated difference in
spacer acquisition rates for the two CRISPR systems (Figure 3.2.1-C), we
generated a probabilistic model to predict how many phage infections it would
take to reach this point of diminished immunity (Figure 3.2.2-F). Based on this
model, we predict that while spacers in SthCRISPR01 would become
significantly weaker after approximately 4 new phage challenges, the spacers
stored in SthCRISPR03 could maintain their potency for approximately 40 rounds
of new phage challenges. Taken together, our data support a model in which
Streptococcus thermophilus can form both long- and short-term immunological
memories by harboring two CRISPR systems that acquire new spacers at
different rates.
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Leader-repeat junction specificity underlies orthogonal spacer storage in S.
thermophilus
For the two Type II-A CRISPR systems to acquire spacers at different
rates within the same cell, the two CRISPR systems have to acquire spacers
independently of one another. If crosstalk were possible, then the more active
spacer acquisition machinery could exhibit a dominant phenotype where both
systems rapidly acquire new spacers. Given their ability to acquire spacers at
different rates even when we expressed them in the same cell, we speculated
that the two related CRISPR systems have evolved mechanisms that allow them
to acquire new spacers independently of one another and avoid crosstalk during
spacer integration.
While it has been previously demonstrated that the two systems are able
to process crRNAs and interfere independently, the possibility of crosstalk during
spacer acquisition has not yet been addressed. To test our hypothesis, we
analyzed the spacer sequences inserted into each CRISPR locus in our early
time point next-generation sequencing experiment. We were able to use PAM
sequences (CRISPR01: NNAGAAW; CRISPR03: NGGNG34) to assign spacers
inserted into each array to the spacer integration machinery of each system. We
found that spacer acquisition was highly accurate for both CRISPR01 and
CRISPR03 (Figure 3.3.1-A&B). For phage-targeting spacers, both systems were
greater than 90% accurate (Figure 3.3.1-A; means of 275.103 vs. 0.395 spacers
for CRISPR01 and 4.460 vs. 0.345 spacers for CRISPR03, mean values in RPM
for n = 3). Because of the high sensitivity of the PCR-based assay we used, we
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were also able to detect self-targeting spacer acquisition against the host
chromosome. For spacers matching the host chromosome, we also observed
high specificity for both systems (CRISPR01=96.686% and
CRISPR03=99.306%; Figure 3.3.1-B). This experiment demonstrates that while
crosstalk is possible between the two systems during spacer acquisition,
mechanisms have evolved to minimize crosstalk and thereby increase the
efficiency of the system.
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Figure 3.3.1. Sequences at the leader-repeat junction prevent crosstalk
between Type II-A CRISPR systems during spacer acquisition.
(A&B) Deep sequencing analysis of spacer integration accuracy in the two
CRISPR systems at an early time point against (A) the phage genome and (B)
the host chromosome. (C) Comparison of the leader-repeat junctions in the two
Type II-A CRISPR systems of S. thermophilus LMD-9. (D-G) PCR analysis of
spacer acquisition in arrays with mutations in the leader-repeat junction of the
(D&E) CRISPR01 and (F&G) CRISPR03 loci (* denotes mutant tracrRNA
background).

We next sought to probe the mechanisms that enable orthogonal spacer
acquisition in these two co-existing CRISPR systems. Type II-A CRISPR
systems have been shown to not require host factors for site-specific spacer
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integration but rather rely on interactions between the Cas1-Cas2 integrase, the
leader anchoring sequence (LAS), and the repeat sequence13,14,19. We wondered
whether differences in the leader-repeat junction of the two CRISPR systems
were important for reducing crosstalk during spacer acquisition (Figure 3.3.1-C).
To test determinants of specificity for the spacer acquisition machinery of each
system, we introduced a variety of plasmids containing mutations in either the
leader or repeat sequences. To test the importance of the leader, we replaced
the entire leader sequence with the leader of the other system. For the repeat,
we swapped bases that differed in the first six and last twelve nucleotides of the
repeat sequence, as these regions were identified as important for spacer
integration. We also made compensatory mutations in the tracrRNA to preserve
base pairing interactions104, which allowed for proper interference from these
arrays (Figure 3.3.2). Replacement of the SthCRISPR01 leader with the
sequence from the SthCRISPR03 leader significantly diminished spacer
acquisition activity (Figure 3.3.1-D). We were then able to narrow down the
relevant region to the LAS, as just swapping the two nucleotides that differ
between the LAS’s was sufficient (Figure 3.3.1-E) and reverting those two
nucleotides in the SthCRISPR03 leader was also sufficient to restore spacer
acquisition activity in the leader swap construct (Figure 3.3.1-E). Mutations in the
repeat sequence, however, had little or no effect on spacer acquisition activity
(Figure 3.3.1-D). These results demonstrate the importance of the leader-repeat
junction in site-specific spacer integration for SthCRISPR01 and suggest a
primary role for the LAS in aiding the integrase to discriminate between CRISPR
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loci. In contrast, we found that the leader sequences were interchangeable for
SthCRISPR03 (Figure 3.3.1-F). Rather, altering the repeat sequence diminished
spacer integration activity for SthCRISPR03 (Figure 3.3.1-F). We tested the
importance of both the 5’ and 3’ ends of the repeat individually, and both
appeared to be sufficient for reducing spacer integration activity (Figure 3.3.1-G).
Thus, we conclude that SthCRISPR01 and SthCRISPR03 have evolved distinct
mechanisms by which they distinguish between CRISPR arrays during spacer
integration, allowing the two coexisting CRISPR systems to efficiently defend the
host.

Figure 3.3.2. Compensatory mutations in the tracrRNA enable interference
with mutated repeat sequences.
(A&B) Efficiency of plaquing analysis of interference from the native spacer 1 in
(A) CRISPR01 or (B) CRISPR03 in various configurations of repeat and tracrRNA
mutations.
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3.3 DISCUSSION
By stably incorporating segments of foreign DNA into arrays, spacer
acquisition enables a specific and adaptive immune response to foreign threats
for both the prokaryotic host and its progeny100. However, addition of new
spacers weakens the immunity provided by existing spacers by pushing them
further downstream within the array as well as by a dilution effect from the
increased number of total spacers19,101. We propose that for bacteria that face a
diverse or rapidly mutating population of phages, evolutionary pressures will
select for CRISPR systems that acquire new spacers at higher rates. In contrast,
for bacteria that are faced with recurring infections by similar or related phages, it
would be more beneficial to preserve the potency of existing spacers by
acquiring new spacers less frequently.
Infection of a population of CRISPR-containing cells yields a
heterogeneous population with a rich diversity of spacer sequences48. Selective
pressures imposed by the phage population can then shape the distribution of
spacers in the bacterial population20. It is common for bacteria to harbor multiple
CRISPR loci (Figure 3.4.1-A). In that scenario, these phage-enforced selective
pressures can also shape the distribution of spacers across the different CRISPR
arrays. When the coexisting CRISPR systems belong to different types, it is
reasonable to speculate that selective advantages conferred by distinct targeting
mechanisms of the different effector complexes would determine which system
adapts to a particular threat62. However, it is less clear what advantages would
be conferred by having multiple CRISPR systems of the same type and even
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subtype. Here, we have demonstrated that two Type II-A CRISPR systems of
Streptococcus thermophilus can independently add new spacers at different
rates to form both short- and long-term immunological memories. We postulate
that selective pressures could determine which CRISPR system is used by the
bacterial population to adapt to new phage threats. For spacers that target a
broad range of phages or a recurring threat, spacers stored in the low-frequency
system will have an advantage and will thus be selected for on a population level.
In contrast, for spacers that respond to a new threat that is not persistent, the
high-frequency system will be able to rapidly neutralize the threat but potency of
this spacer will not need to be preserved. Each CRISPR system could also
benefit the cell differently depending on the ecological niche currently occupied
by the cell. In niches with high dispersal of phages, a fast-responding CRISPR
system would be more beneficial due to the diversity of phage likely to be
encountered. In contrast, in ecological niches with low phage dispersal, a lowfrequency system would be more beneficial because phage infections are more
likely to be recurring and maintaining the potency of acquired spacers would be
more beneficial for the population. Our results reveal that intrinsic differences in
spacer acquisition endows each system with a unique set of benefits and enable
them to work together to form a robust anti-phage defense system.
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Figure 3.4.1. Natural variation in rates of spacer acquisition may be
genetically encoded.
(A) Analysis of the number of CRISPR loci harbored in various prokaryotic
genomes. (B) Comparison of BIM formation in the CRISPR system of
Streptococcus mutans NN2025 harboring either WT or mutated Cas9. (C)
Comparison of the number of spacers in native CRISPR arrays from Group 1 and
Group 2 Type II-A CRISPR systems.

We have also demonstrated that the two Type II-A CRISPR systems of S.
thermophilus have evolved genetic isolation from one another. We have shown
that specific interactions between the Cas1-Cas2 integrases and the leaderrepeat junctions enable orthogonal storage of spacers. This allows for the two
Type II-A systems to maintain different rates of spacer uptake and give their
existing spacers different longevities. CRISPR systems have been categorized
by their effector cas genes that deal predominantly with the interference phase of
CRISPR immunity. However, our results reveal that functional differences in
spacer acquisition can exist among similarly classified CRISPR systems.
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Previously, our lab demonstrated that by introducing mutations in the cas9
gene of the Type II-A CRISPR system from Streptococcus pyogenes it was
possible to increase the rate of spacer acquisition50. Here, we report that natural
variation in the rates of spacer acquisition also exists among Type II-A CRISPR
systems. While it remains technically challenging to experimentally address the
differences in rates of spacer acquisition we observe, we have some hints at
mechanisms that underlie this variation. For instance, we noticed a leucine
residue in the 500th amino acid of the Cas9 from the CRISPR system from
Streptococcus mutans that exhibits a high frequency of spacer acquisition. This
was similar to a mutation (Cas9K500I) that we previously reported as offering a
small increase in the rate of spacer acquisition50. We introduced the reciprocal
mutation into the Streptococcus mutans system (Cas9L500K) and noticed a
modest decrease in the rate of spacer acquisition (Figure 3.4.1-B), suggesting
that this is a naturally occurring hyper-Cas9 mutation. For the Streptococcus
thermophilus CRISPR systems, we noticed that they belong to two separate
clades of Type II-A CRISPR systems (SthCRISPR01 and SthCRISPR03 belong
to Group 1 and Group 2, respectively). When we divide our spacer content data
(Figure 3.1.1-A) by Type II-A Groups, we find that the mean number of spacers
for Group 1 Type II-A systems is double that of Group 2 (p = 0.0004; Figure
3.4.1-C). This suggests that these two clades of CRISPR systems have diverged
for rates of spacer acquisition as well as interactions between Cas1 and the
leader-repeat junction. Notably, SthCRISPR03 and SpyCRISPR share the most
sequence homology among this collection of Type II-A CRISPR systems and
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exhibit comparable rates of spacer acquisition. Together, these observations
suggest a genetic basis for the differences we observed in spacer acquisition
rates. As our understanding of the molecular details of spacer acquisition
increases, it will be interesting for future studies to more directly address the
molecular basis for the variation we observe in rates of spacer acquisition.
Similarly, comparative analysis of spacer acquisition in related but functionally
distinct CRISPR systems could yield a better understanding of the molecular
basis of CRISPR immunity.
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CHAPTER 4: PERSPECTIVES
CRISPR-Cas systems comprise a genetic immune system to safeguard
bacteria and archaea from invading threats by storing fragments of foreign DNA
in CRISPR arrays within the host genome. Once transcribed, these foreignderived sequences, called spacers, provide sequence-specificity for CRISPRassociated (Cas) nucleases to destroy viruses, plasmids, and other potentially
lethal threats. By stably storing spacers in the genome, CRISPR immunity is both
adaptive and heritable99,100.
In my thesis work, I have explored how CRISPR systems store and
organize their molecular memories of past invaders and the functional
consequences of this process. By studying the Type II-A CRISPR locus from
Streptococcus pyogenes, I identified a crucial regulatory region of the CRISPR
locus that determines the site of spacer integration within the CRISPR array,
which I termed the leader-anchoring sequence (LAS). The LAS enforces
polarized addition of spacers to the array such that the chronological order of
spacer acquisition is preserved. Mutation of the LAS leads to erroneous
integration of new spacers into the middle of the array. Further, I demonstrated
that spacers positioned near the LAS provide more robust immunity than spacers
positioned further downstream. Therefore, CRISPR systems can utilize the
chronological organization of spacers within the array to prioritize their immune
resources against the most recent invader19.
Two complementary studies corroborated my findings through biochemical
and structural approaches13,14. Wright et al. (2016) demonstrated the importance
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of the LAS during spacer integration in an in vitro spacer integration assay14. This
study revealed that improved reaction kinetics on the leader-end of the array,
presumably from additional contacts made between the spacer integration
machinery and the LAS, resulted in spacer integration preferentially occurring at
the leader-end of the array. This was subsequently confirmed by Xiao et al.
(2017) in their structure of the Cas1-Cas2 complex from a Type II-A system in
complex with the integration target substrate13. This structure revealed that an αhelix from Cas1 inserts itself into the minor groove of the leader DNA to make
direct, sequence-specific contacts with the LAS. Taken together, we now have a
mechanistic understanding of how spacer acquisition is polarized in Type II
CRISPR immune systems.
Less clear, however, is the precise mechanism by which position within a
CRISPR array affects the level of immunity that it provides. In Chapter 2, I
demonstrated that altering the position of the same spacer sequence within the
array modulated the abundance of the corresponding crRNA by two-fold19. While
this difference is modest, it is possible that other aspects of the CRISPR immune
response could amplify this difference (i.e. that Cas9 is a single-turnover
enzyme27). Further experimentation will be needed to fully tease apart this
mechanism. For example, it would be informative to look at differences in crRNA
loading into Cas9 that arise from positioning of the spacer within the CRISPR
array. In addition, little is known about crRNA transcription, processing, and
loading into Cas9 for Type II-A CRISPR systems, so it remains possible that
other aspects of these processes are affected by spacer position within the array.
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In particular, it could be valuable to determine the kinetics of crRNA biogenesis
after the spacer has been newly integrated into different positions within the
array. Of course, in vitro reconstitution would provide crucial insights into this
process. The uneven distribution of crRNA expression has been observed in
many CRISPR systems and appears to be a general trend for CRISPR immune
systems19, so it could be informative to look at the generality (or variation) in
mechanisms that underlie this feature of CRISPR immunity. Notably, a strain
harboring a natural mutation in its LAS has recently been identified and it was
confirmed to result in ectopic spacer integration105. Why (and if) a mutation in the
LAS would be selected for is unclear, but it could imaginably serve as a way to
bypass strict chronological storage of spacers and give rise to a more complex
organizational system.
While spacer acquisition provides the immediate and significant benefit of
immunity, it can also impart a cost on the system by weakening the immunity
provided by existing spacers by shifting them further downstream within the
array. Also, it has been shown that increasing the absolute number of spacers in
an array has a detrimental effect on the immunity provided by a single spacer,
presumably by a dilution effect101. To explore how bacteria deal with this
conundrum, I examined differences in spacer acquisition rates across a variety of
related CRISPR systems. I found striking differences in the rates of spacer
acquisition across Type II-A CRISPR systems, including two systems that coexist
in Streptococcus thermophilus. By harboring CRISPR systems that acquire new
spacers at different rates, the bacterial population can store spacers for short-
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and long-term utility. Thus, immunological memories are organized not only
within CRISPR arrays but also across CRISPR arrays to ensure optimal
immunity.
On the flip side of spacer acquisition, spacers can also be lost from the
array28,29, though this process is poorly understood. The rates of spacer loss from
CRISPR arrays, as well as the mechanistic basis of spacer loss, have not been
properly studied. However, my work has suggested that spacer loss can be
functional and selected for. When phage-targeting spacers are downstream in
the array, deletion of upstream spacers can boost the immunity provided by the
spacer by repositioning it within the array19. Future studies investigating deletion
and recombination within and across arrays will provide valuable insights into
CRISPR evolution and biological memory.
Many bacteria harbor multiple CRISPR systems, both of the same type
and different types. However, many questions remain regarding the functional
consequences and benefits of these configurations. Further, what advantages
and disadvantages correspond to the different types of CRISPR systems has not
been studied. Exploration of the benefits and costs associated with different
CRISPR systems can shed light on why bacteria harbor multiple types of
CRISPR systems as well as reasons underlying the diversification of CRISPR
systems.
That around half of sequenced bacterial genomes do not contain CRISPR
systems hints at there being deleterious consequences associated with having a
CRISPR system, but this has not been fully addressed100. The fact that some
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CRISPR systems, i.e. Type III loci, can frequently be found without spacer
acquisition-related genes suggests that the adaptive nature of CRISPR systems
can itself be detrimental to the cell62,89. This could possibly be due to costs
associated with autoimmunity resulting from acquisition of spacers against the
host genome50,106. Another potential cost of having a CRISPR system could be
limiting beneficial horizontal gene transfer, as we know that a number of
sequenced spacers map to plasmids and other mobile genetic elements3,76.
CRISPR-Cas systems, and spacer acquisition in particular, represent a
unique form of bacterial evolution, in that they provide a quasi-Lamarckian
mechanism to adapt against genetic threats. What impacts CRISPR immunity
and spacer acquisition have on the evolution of bacterial genomes remains
unaddressed. Perhaps most interestingly is that a spacer acquisition event is a
clear example of a hard selective sweep in a bacterial population. While the initial
population recovering from a new phage infection is heterogeneous (with many
spacer sequences in the population48), eventually purifying selection results in
homogenized populations (uniformity can be observed in downstream spacers
within the array20). Are beneficial traits unrelated to CRISPR immunity lost
because of this loss of genetic diversity? Conversely, what traits or genes can
use this as a means for genetic hitchhiking? If CRISPR immunity does have a
large impact on shaping genome evolution or limiting genetic diversity in bacterial
populations, it is tempting to speculate that this could be a reason for bacteria to
not harbor CRISPR systems (or at least spacer acquisition competent ones) in
their genomes.
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More ecological and metagenomic approaches will expand the depth and
breadth of our understanding of CRISPR biology. A great majority of CRISPR
studies are conducted under specific sets of idealized conditions that likely do not
faithfully recapitulate natural environmental contexts (this is not exclusive to
CRISPR and is a general limitation of many microbiological studies). Studies of
bacteria-phage interactions using log-phase cultures grown in rich media are not
likely to accurately reflect the majority of such interactions in nature. For
instance, the vast majority of bacteria on the planet are in a non-replicative
state107. This has significant implications for how we view CRISPR biology. For
instance, it has been experimentally demonstrated that lytic phage programs
cannot be initiated in dormant cells, but the lytic cycle can resume when the cell
exits dormancy108. How does this impact spacer acquisition? Is our assessment
of spacer acquisition as a rare event (~10-7) a gross underestimate? If spacer
acquisition could still proceed in a non-replicative cell in which phage replication
is stalled, then perhaps the cell can take advantage of this extra time to acquire
new spacers. In this case, spacer acquisition could actually be quite common
within a population. Relatedly, in populations that are exponentially growing, do
persister cells represent a non-genetic phenotypic subpopulation that acquires
spacers at higher rates? Generally, how cell metabolism and growth state affect
CRISPR immunity remains largely unexplored but is a promising area for future
study.
Another limitation of current experimental studies of spacer acquisition is
that the majority ignores lysogeny as an option for cells to gain phage resistance.
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Prophages are rampant in sequenced bacterial genomes and can offer protection
against related phages through superinfection exclusion and against other
phages by a variety of other phage exclusion mechanisms109. It will be
informative to study spacer acquisition against lysogeny-competent temperate
phages. For example, it would be interesting to explore the balance between
lysogeny-mediated and CRISPR-mediated phage resistance and how
environmental conditions affect the balance between these two mechanisms.
Recently, spacer acquisition has been the basis of a variety of new DNAbased information and memory storage systems110. In addition to this, CRISPRCas systems have been widely repurposed for a variety of technological
applications, ranging from genome editing111 to point-of-care diagnostics112.
Altogether, these CRISPR-enabled technological advances have already
revolutionized the world of biology and medicine, ushering in a new era of
genome manipulation. But still, the unique and surprising biology of CRISPR
immune systems in their native microbial world has a wealth of mysteries waiting
to be unraveled.
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CHAPTER 5: MATERIALS AND METHODS
Bacterial strains and growth conditions
Cultivation of S. aureus RN422092 was carried out in brain-heart infusion
(BHI) or heart infusion (HI) media (BD) at 37°C. When applicable, media was
supplemented with chloramphenicol (10 µg/mL), erythromycin (10 µg/mL) or
spectinomycin (250 µg/mL) to ensure maintenance of the pC194-derived113,
pE194114, or pLZ12-derived115 plasmids, respectively.
Simulation of CRISPR immunization
Overnight cultures were diluted 1:100 into fresh BHI supplemented with
appropriate antibiotics and 5 mM CaCl2. These cultures were then grown to an
OD600 of 0.2-0.4, upon which they were normalized to OD600 = 0.2. Position 1 and
Position 5 strains were diluted 1:10,000 into the sensitive strain RN4220 in
triplicate. The mixed cultures were infected with phage ΦNM4γ4 at an MOI of 1.
Growth of the cultures was detected measuring OD600 using plate reader.
Plasmid construction
The plasmid containing the wild-type Streptococcus pyogenes CRISPR
(pWJ40) was described elsewhere48. The sequences of all the oligonucleotides
used in this study are shown in Table S1. DNA sequences obtained by gene
synthesis (Genewiz, Inc.) are shown in the accompanying Supplemental
sequences file. Leader deletion 78-102 (pJM13) was constructed by two-piece
Gibson assembly116 from pWJ40 using the primer pairs JM118-JM91 and JM90JM112, respectively. Leader deletions 88-102 (pJM23), 98-102 (pJM25) were
constructed by one-piece Gibson assembly from pWJ40 using the primer pairs
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JM118-JM132 and JM118-JM134, respectively. Leader mutation -5 to -1 (pJM28)
and -10 to -6 (pJM29) were constructed using one-piece Gibson assembly from
pWJ40 using the primer pairs JM139-JM140 and JM141-JM142, respectively.
pJM37 (swap of spc2 and spc4) was constructed by inserting the array with BsaIcompatible overhangs in place of flanking repeats into pDB184 58. The swapped
array sequence for pJM37 was obtained by gene synthesis. pJM70 (pJM37 with
LAS mutation) was constructed by two-piece Gibson assembly from pJM37 using
the primer pairs JM139-JM91 and JM140-JM90. pJM62 (pWJ40 with BsaIcloning site for array cloning) was constructed by two-piece Gibson assembly
from pWJ40 using the primer pairs JM210-JM173 and JM211-JM172. pJM73
(insertion of LAS in place of spc4) was constructed by inserting the array with
BsaI-compatible overhangs in place of flanking repeats into pJM62. The array
sequence for pJM73 was obtained by gene synthesis. pJM111 (LAS
mutant Δspc4) was constructed by around-the-horn PCR117 using primers JM318
and JM319 to remove spacer 4 and one repeat from the pJM28 CRISPR array
template. pJM74 (pJM73 with LAS mutation) was constructed by two-piece
Gibson assembly from pJM73 using the primer pairs JM139-JM91 and JM140JM90. pJM86 [pJM62 with dCas1 (E220A)] was constructed by two-piece Gibson
assembly from pJM62 using the primer pairs JM172-PS285 and JM173-PS284.
pRH253 (pWJ40 with spacer targeting phage ΦNM4γ4) was isolated during an
on-plate spacer acquisition assay48. pJM87 (Position 5, dCas1, pC194-derived)
was constructed by inserting the array with BsaI-compatible overhangs in place
of flanking repeats into pJM86 The array sequence for pJM87 was obtained by
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gene synthesis. pJM90 (Position 1, dCas1, pC194-derived) was constructed by
two-piece Gibson assembly from pRH253 using the primer pairs JM172-PS285
and JM173-PS284. pJM141 (Position 5, dCas1, pLZ12-derived) and pJM142
(Position 1, dCas1, pLZ12-derived) were constructed by three-piece Gibson
assembly from pJM87 and pJM90, respectively, and pLZ12 using the primer
pairs JM350-JM173, JM351-JM172, and JM352-JM353.
The plasmid containing the Streptococcus thermophilus LMD-9
CRISPR03 was described elsewhere48. The plasmid containing Streptococcus
thermophilus LMD-9 CRISPR01 was cloned using Gibson assembly using pC194
and Streptococcus thermophilus LMD-9 genomic DNA as templates with primers
JM409, JM411, JW155, JW156. The plasmid containing the Streptococcus
mutans NN2025 CRISPR locus was cloned using Gibson assembly using pC194
and Streptococcus mutans NN2025 genomic DNA as templates with primers
JM386, JM389, JM511, JM512. Derivatives of these plasmids were constructed
using Gibson assembly (details available upon request). Streptococcus
thermophilus CRISPR arrays with different spacers were constructed using
Gibson assembly and synthesized DNA constructs purchased from Genewiz.
Spacer acquisition assay in liquid cultures
In-liquid spacer acquisition assays were performed using a slightly
modified method described in 48. Overnight cultures were diluted 1:100 in fresh
BHI with appropriate antibiotics and 5 mM CaCl2 and grown to OD600 = 0.5.
Cultures were then infected with phage ΦNM4γ4 at a MOI of 1 phage per
bacterium, unless otherwise noted, and incubated with shaking at 37°C for 24
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hours. For Sanger sequencing, cultures were streaked onto a fresh BHI-agar
plate containing the appropriate antibiotics. Plates were incubated overnight at
37°C. Single colonies were picked and incubated in lysis buffer (250 mM KCl, 5
mM MgCl2 50 mM Tris-HCl at pH 9.0, 0.5% Triton X-100) for 20 minutes at 37°C
and then 98°C for 10 minutes. 1 µl of supernatant was then used as template for
PCR amplification using TopTaq Master Mix Kit (Qiagen).
For Streptococcus pyogenes CRISPR spacer acquisition, primers
JM116/H050 were used for detecting wild-type spacer integration, JM171/JM119
were used for detecting ectopic spacer integration, and JM116/JM119 were used
for amplification of the entire array.
For Streptococcus thermophilus CRISPR spacer acquisition, primers
JM439/JM440 and H169/H267 were used for CRISPR01 and CRISPR03
respectively.

Adaptation competition assay
Overnight cultures were diluted 1:100 into fresh BHI with appropriate
antibiotics and 5 mM CaCl2 and grown to OD600 = 0.4-0.6. The cultures were then
normalized by OD600 and mixed in a 1:1 ratio. This mixed culture was then
infected with phage ΦNM4γ4, in triplicate, at an MOI of 1 for 24 hours, upon
which the culture was streaked onto a BHI agar plate containing appropriate
antibiotics. Colonies were subjected to PCR using the primers JM116/JM119 for
identification of the strain and analysis of spacer integration via Sanger
sequencing of PCR products.
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Bacterial growth curves during phage infection
Phage infections and plate reader growth curves were performed as
previously described58 with slight modifications. In brief, overnight cultures were
diluted 1:100 into 2 ml of fresh BHI supplemented with appropriate antibiotics and
5 mM CaCl2. These cultures were then grown to an OD600 of 0.4-0.6, upon which
they were infected with phage ΦNM4γ4. To produce plate reader growth curves,
150 µl of infected cultures, normalized for OD600, was transferred to a 96-well
plate in triplicate. OD600 measurements were taken every 10 minutes.

Phage titer assay
Phage titer assays were performed as previously described48.

Detection of spacer integration events using next-generation sequencing
Overnight cultures were diluted 1:100 in fresh BHI containing the
appropriate antibiotics. At OD600 = 0.5, the cultures were infected with phage
ΦNM4γ4 at an MOI of 1. After 24 hours, plasmids were isolated from the cultures
using the QIAprep Spin Miniprep Kit protocol as previously described48. 100 ng of
plasmid DNA served as template for PCR amplification using Phusion HighFidelity DNA Polymerase (Thermo Scientific) and 6 barcoding primer sets
(H188/JM257, JM248/JM258, JM249/JM259, JM250/JM260, JM251/JM261, and
JM252/JM262). After gel extraction and purification of the DNA bands
corresponding to expanded CRISPR arrays, the DNA was subjected to
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sequencing by Illumina MiSeq (600 cycles). Reads were filtered by quality score,
sorted by barcode, and subsequently converted to .txt format using a custom
Python script that utilized Biopython. Other custom Python scripts were
employed to create a list of reads, normalized to total number of reads per
barcode, that met the following criteria: reads must contain 7 spacers and 8
repeats, the pre-existing spacers must be in the correct order, and the new
spacer must have at least 15 bp matching the phage genome.
For early time point deep sequencing, cultures were harvested at 30
minutes post infection with ΦNM4γ4 at an MOI of 1 and then miniprepped as
described above using the modified lysostaphin protocol. PCR with Phusion
polymerase was used to amplify the CRISPR arrays using a special primer set
designed to amplify low-frequency spacer integration events as done
previously48. The primers used here were JM472-479. Size selection was done
using a modified Illumina library preparation protocol as described previously41,48.
Custom Python scripts and BWA118 were used to analyze the deep sequencing
data and assign PAMs to unique spacer reads based on genome alignment.

Preparation of electrocompetent S. aureus cells
Electrocompetent S. aureus cells were prepared and transformed with
DNA using a previously described method58, with the exception of using BHI
medium instead of TSB medium.

Mathematical modeling of dual CRISPR system spacer acquisition
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A probabilistic model was generated using a custom Python script which
assumed a 9:1 spacer acquisition ratio for CRISPR01:CRISPR03. The average
values over one hundred iterations was used for the model presented here.

Leader sequence alignments
Related type II-A CRISPR systems were selected based on previous work
that classified these systems93. Multiple sequence alignment was performed and
visualized using T-Coffee119.

Bioinformatic analysis of Type II-A CRISPR systems
The databases entitled CRISPRdb (http://crispr.i2bc.parissaclay.fr/crispr/)120 and CRISPI (http://crispi.genouest.org/)121 were used to
collect data on CRISPR array length and other characteristics of CRISPR
systems. The list of CRISPR systems was compiled based on a previous
analysis of Type II-A CRISPR systems103.

Total RNA extraction
Total RNA was extracted as described in Jiang et al. 2016122 with minor
modifications. Briefly, 6 ml of S. aureus culture was pelleted and was
resuspended in 1 ml of TRIzol (Thermo Fisher Scientific). The cell suspension
was transferred to 2 ml-tubes pre-filled with 0.25 cm3 of 0.1 mm glass beads on
ice. Cells were disrupted twice at 4°C, using MiniBeadbeater-1 (BioSpec
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Products) at an intensity setting of 42 for 30 seconds. 200 µl of chloroform was
added to the mixture and the remainder of the RNA extraction was carried out
according to the Trizol manufacturer’s instructions.

Small RNA library preparation and next-generation sequencing of RNA
Small RNA libraries were prepared with the TruSeq Small RNA Library
Preparation Kit (Illumina) using 2 µg of total RNA extracted from cultures at
OD600 = 0.5. Reverse transcribed and PCR-amplified RNA species between 30
and 55 nt were purified by gel extraction and ethanol precipitation. The purified
DNA was subjected to next-generation sequencing by Illumina MiSeq (150
cycles). Reads were sorted by index and converted to .txt format using a custom
Python script that utilized Biopython. Other custom Python scripts were used
analyze crRNA abundance.
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Oligonucleotides used in this study
Name

Sequence

JM1

CTATGCAGAAGACCTTCAAGAAAG

JM2

CATCTTAGCTTGGTAATCTTCCTTG

JM3

TCTCACTTACTAAGTCACAAGGAAGATT

JM4

AATCTTTTTTCAACAATTGATAAAAATC

JM5

CACGATGGATGGTTGGCTATT

JM6

ATAGAAATTGAGAATAAACTACATTTGATG

JM7

TTGATCCCGAAACAGTTCATAGT

JM8

GCTAATCGTCCTAACGTACCTAGAC

JM9

TCATAGGGCATCTGGAACGC

JM10

TCAAATCCACTAGTTCTCCTGTTTCTA

JM11

AGGAAATCATTGGACTTATGAAAGAC

JM12

ATGTAATCAGCGAAGCGTTCC

JM13

TAAACAATCTCGCATGATATCAAAA

JM14

AAATAAAGAATAGCGTGTCAATGCT

JM15

CCACAGTTTATGGCATCAATATAAC

JM16

ATCTATTGGTTGGTCGGGATTT

JM17

GATTGGACATTACAACAATTAGTAGATTAC

JM18

AATCTGCATAACCATTTTCTTTTAAT

JM19

TTAACAATTAAACCATGTGAGACATTT

JM20

CTTGTTCACTATCTAAATCAATGATTGTT

JM21

TGAAAATGCAGCATGTCATTTAG

JM22

TAATCCGCTTGCAATCTTTTC

JM23

GGATCTGCTTACGCCTTTAATATT

JM24

TGAAATCGACATGTACATTTGAATC

JM25

GTTTGACGTATCATACATACCTTGC

JM26

CTAAATGCGAACAAACCACGA

JM27

TAAACAAATACTTAAAGATGACGGTGA

JM28

GTACATTCCAAATTGCGACATACTT

JM29

AATCAGATGAGTATTTAATAACAGAATTATCA

JM30

GCAGAATAAATATTTGTAATGATAGCG

JM31

AATTATTAGGTATTGAGAAATATAAACCACA

JM32

TTTTGATAGTTCTCTAACGTTTCATGG

JM33

GTCAAAATATTAAACCAGTTTATAAAATGG

JM34

TCATTTTCATCTTCATACGTACCATAA

JM35

ATACATGTGCAGCTGAATTTGAAT

JM36

CTAGTACTAGAATTTTCTCTTTATCAGTTACTATAG

JM37

aaacATTGTTTATCTACCATGTAATAGTAAAAAAg

JM38

aaaacTTTTTTACTATTACATGGTAGATAAACAAT
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JM39

aaacCCCATTATTATATACGCATTTTGTAAAAAAg

JM40

aaaacTTTTTTACAAAATGCGTATATAATAATGGG

JM41

aaacCATTTTCATCAAATAAAGTATTGTAAAAAAg

JM42

aaaacTTTTTTACAATACTTTATTTGATGAAAATG

JM43

CAGATCAAGAAATCAAACTCCAA

JM44

CAGCATCATCTACAGAAACTC

JM45

CGTTATAAGGGGCTAGGTGAAA

JM46

CAGCATCATCTACAGAAACTCTAGC

JM47

CCGATTGCTCTAGTAAAAGTCCTG

JM48

CGTAATGGTAAAATCGCCTGC

JM49

AGTTGATATTCAAGAAAAAATGGGA

JM50

AGATACTTTGTATCCGCCACCG

JM51

TGTTGATAATAGTATTGACGAGGCATTAGC

JM52

GTGAAGACCGCCAGAT

JM53

AGAAAAGATGGGACGCCCT

JM54

GTGAAGACCGCCAGATACTTTG

JM55

GATTGAAAATGCAGCTTACTTTGTAAAAAAgttttagagctatgctgttttgaatg

JM56

TTTTTTACAAAGTAAGCTGCATTTTCAATCgttttgggaccattcaaaacagc

JM57

AGGGCTTAACAAAACTAGATTTGTAAAAAAgttttagagctatgctgttttgaatg

JM58

TTTTTTACAAATCTAGTTTTGTTAAGCCCTgttttgggaccattcaaaacagc

JM59

GCCCTATGATATAAAGGTATTGAGTTCCATgttttagagctatgctgttttgaatg

JM60

ATGGAACTCAATACCTTTATATCATAGGGCgttttgggaccattcaaaacagc

JM61

tcaaggtaagtatgtgattaaagcaac

JM62

attgggctcgactatatcttgaa

JM63

caatttgcgcttaactcttttg

JM64

gaataagttcatcgaattcattaccac

JM65

CACTAATTTCCCTTCCATCGCTCTTTGG

JM66

CGATTGCTTCTATTATGCGTTGTTGTTCGG

JM67

CGTTCTAGGGCTTAACTTCTGTGTTCG

JM68

CAGCAAACTTCCCATAATGTTTCCCATCATCACCAC

JM69

CCAGACCATTGATTACATTTCTGAGCAATCACAGGG

JM70

ATGACACCAGAACAACTTAAAGCA

JM71

TATACTTTTCACCCTTTTCAGTATCAC

JM72

TACTCTTAATAAATGCAGTAATACAGGGGCTTTTCAAGACTGAAGTCTAGCTGAGACAAATAGTGCGATTACAAAATTTTTTAGACAAAAATAGTCTACGAG

JM73

CTCGTAGACTATTTTTGTCTAAAAAATTTTGTAATCGCACTATTTGTCTCAGCTAGACTTCAGTCTTGAAAAGCCCCTGTATTACTGCATTTATTAAGAGTA

JM74

GAAATTAATACGACTCACTATAGGGGTTGGAACCATTCAAAACAGCATAGCA

JM75

AAAAAAAGCACCGACTCGGTGC

JM76

GAUUUCUUCUUGCGCUUUUUGUUUUAGAGCUAUGCUGUUUUG

JM77

TAATGAATTCCCCAATACCCCTAAAGAAGAACGCGAAAAAAACCAGCGCA

JM78

TGCGCTGGTTTTTTTCGCGTTCTTCTTTAGGGGTATTGGGGAATTCATTA

JM79

CTTTGAGCTTCCGAGACTGGTCTC
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JM80

CAGCATAGCTCTAAAACCTCGTAGACTATTTTTGTC

JM81

ctcgtagactatttttgtctaaaaaatttCgtaatcgcac

JM82

agatgaagattatttcttaataactaaaaatatggtataaTGAGACAAATAGTGCGATTA

JM83

TAATCGCACTATTTGTCTCAttataccatatttttagttattaagaaataatcttcatct

JM84

AGACTGAAGTCTAGCgttttagagctatgctgttttgaatggtcccaaaactgagaccag

JM85

ctggtctcagttttgggaccattcaaaacagcatagctctaaaacGCTAGACTTCAGTCT

JM86

AGATGAAGATTATTTCTTAATAACTAAAAATATGGTATAAggggcttttcaagactgaag

JM87

cttcagtcttgaaaagccccTTATACCATATTTTTAGTTATTAAGAAATAATCTTCATCT

JM88

GTGCGATTACGAAATgttttagagctatgctgttttgaatggtcccaaaactgagaccag

JM89

ctggtctcagttttgggaccattcaaaacagcatagctctaaaacATTTCGTAATCGCAC

JM90

GAGAAGATTGAAAAAATCTTGACTTTTCG

JM91

CGAAAAGTCAAGATTTTTTCAATCTTCTC

JM92

caaaagggtttctaatcccattcgaaagcg

JM93

ctctaaaacactcatgagctaagtaagattttccttttc

JM94

GCTAGCAATGAACTTTAATAAAATTGATTTAGACAATTGGAAGAGAAAAGAG

JM95

TTATAAAAGCCAGTCATTAGGCCTATCTGAC

JM96

GTCACTCGAAGATGAAGACTTGATTGAAGAAG

JM97

AAATCAATTTTATTAAAGTTCATTGCTAGCTACTCATTTTCATTATTATTTAGTGAAGTG

JM98

GTCAGATAGGCCTAATGACTGGCTTTTATAAAACAAGAAACTCGCTCTAACGAGTTTC

JM99

ACAGATGAATATAACTGCAAACTCGGATCATC

JM100

tgagaccagtctcggaagctcaaaggtctcAGGGATAAATATGAACATgatgagtgatcg

JM101

CCTgagacctttgagcttccgagactggtctcaAGAGCTCGTGCTATAATTATACTAATT

JM102

ggtataaGactcttaataaatgcagtaatacag

JM103

ctgtattactgcatttattaagagtCttatacc

JM104

ggtataatgggcttttcaagactg

JM105

cagtcttgaaaagcccattatacc

JM106

tgagaccagtctcggaagctcaaaggtctcAGGAGTGATCGTTAAATTTATACTGC

JM107

CCTgagacctttgagcttccgagactggtctcaTGTTCATATTTATCAGAGCTCGTG

JM108

ctcggaagctcaaaggtctcAGGgatgagtgatcgttaaatttatactgcaatcggatgc

JM109

CCTgagacctttgagcttccgaggttcatatttatcagagctcgtgctataattatacta

JM110

Gttttagagctatgctgttttgaatggtcccaaaactgagaccagtctcggaagctcaaa

JM111

ggaccattcaaaacagcatagctctaaaacgctagacttcagtcttgaaaagcccctgta

JM112

ggaccattcaaaacagcatagctctaaaacattttgtaatcgcactatttgtctcagcta

JM113

tatttcttaataactaaaaatatggtataaattttttagacaaaaatagtctacgaggtt

JM114

ttataccatatttttagttattaagaaataatcttcatctaaaatatacTgcggaaaatc

JM115

attcaaaacagcatagctctaaaaCttataccatatttttagttattaagaaataatctt

JM116

gtgaactatatgattttccgcagtatattttagatgaagattatttcttaataac

JM117

GTTTGAACTCAACAAGTCTCAGTGTGCTG

JM118

GTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACTGCGCTGGTTGATTTCTTCTTGCG

JM119

CCCTCTTTCTCAAGTTATCATCGGCAATG

JM120

AAAAAACGTCAGGAGAAGATTCGTAATTTGATGAGTGATCGTTAAATTTATACTGCAATC
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JM121

GACTTCTGGAAGGATCCAAATCACAGAATCGTTCATATTTATCAGAGCTCGTGCTATAAT

JM122

ATTATAGCACGAGCTCTGATAAATATGAACGATTCTGTGATTTGGATCCTTCCAGAAGTC

JM123

GATTGCAGTATAAATTTAACGATCACTCATCAAATTACGAATCTTCTCCTGACGTTTTTT

JM124

ATGGCAGCGCCTAAATGTAGAATGATAAAATACTCTTAATAAATGCAGTAATACAGGGGC

JM125

GCCCCTGTATTACTGCATTTATTAAGAGTATTTTATCATTCTACATTTAGGCGCTGCCAT

JM126

ATGAAGATTATTTCTTAATAACTAAAAATATGGTATAATTAATACCAGCAGTCGGATACC

JM127

GGTATCCGACTGCTGGTATTAATTATACCATATTTTTAGTTATTAAGAAATAATCTTCAT

JM128

GGAGGCTTTTGATGAATCTTAATTTTTCCtaaCTAGATGAACCGATTCCATTAAGAGGCG

JM129

CGCCTCTTAATGGAATCGGTTCATCTAGttaGGAAAAATTAAGATTCATCAAAAGCCTCC

JM130

TGGGACCATTCAAAACAGCATAGCTCTAAAACATTTTGTAATCGCACTATTTGTCTCAGC

JM131

ACCATTCAAAACAGCATAGCTCTAAAACAAAAAATTTTGTAATCGCACTATTTGTCTCAG

JM132

CCATTCAAAACAGCATAGCTCTAAAACTGTCTAAAAAATTTTGTAATCGCACTATTTGTC

JM133

GGACCATTCAAAACAGCATAGCTCTAAAACATTTTTGTCTAAAAAATTTTGTAATCGCAC

JM134

CCATTCAAAACAGCATAGCTCTAAAACAGACTATTTTTGTCTAAAAAATTTTGTAATCGC

JM135

ACGAGGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACTGCGCTGGTTGATTTCTTC

JM136

AGCATAGCTCTAAAACCTCGTTTATACCATATTTTTAGTTATTAAGAAATAATCTTCATC

JM137

AGTCTACGAGGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACTGCGCTGGTTGATT

JM138

AGCTCTAAAACCTCGTAGACTTTATACCATATTTTTAGTTATTAAGAAATAATCTTCATC

JM139

CATCTGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACTGCGCTGGTTGATTTCTTC

JM140

CAAAACAGCATAGCTCTAAAACAGATGAGACTATTTTTGTCTAAAAAATTTTGTAATCGC

JM141

CTGAGACGAGGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACTGCGCTGGTTGATT

JM142

AAACAGCATAGCTCTAAAACCTCGTCTCAGATTTTTGTCTAAAAAATTTTGTAATCGCAC

JM143

CCCCGAGTCTACGAGGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACTGCGCTGGT

JM144

CATAGCTCTAAAACCTCGTAGACTCGGGGTGTCTAAAAAATTTTGTAATCGCACTATTTG

JM145

CTCACAAAATAGTCTACGAGGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACTGCG

JM146

GCTCTAAAACCTCGTAGACTATTTTGTGAGAAAAAATTTTGTAATCGCACTATTTGTCTC

JM147

GAGACAAATAGTGCGATTACAAAATGGGGGAGACAAAAATAGTCTACGAGGTTTTAGAGC

JM148

ACCTCGTAGACTATTTTTGTCTCCCCCATTTTGTAATCGCACTATTTGTCTCAGCTAGAC

JM149

attaatacttcgatacgacaaaacaatggttccaacaagattattttataacttttataa

JM150

gttttgtcgtatcgaagtattaataaggctagtccgttatcaacttgaaaaagtgg

JM151

TGCGCTGGTTGATTTCTTCTTGCGCTTTTTgttaatgtcgatacgacaaaacaatggtcccaaaacttcagcac

JM152

AAAAAGCGCAAGAAGAAATCAACCAGCGCAgttttgggaccattgttttgtcgtatcgacattaacCTCGTAGACTATTTTTGTCTAAAAAATTTTG

JM153

AAAATTTTTTAGACAAAAATAGTCTACGAGGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACTGCGCTGGT

JM154

ACCAGCGCAGTTTTGGGACCATTCAAAACAGCATAGCTCTAAAACCTCGTAGACTATTTTTGTCTAAAAAATTTT

JM155

TAGCTGAGACAAATAGTGCGATTACAAAATGTTTTAGAGCTATGCTGTTTTGAATGGTCC

JM156

GGACCATTCAAAACAGCATAGCTCTAAAACATTTTGTAATCGCACTATTTGTCTCAGCTA

JM157

ATAGTGCGATTACAAAATTTTTTCTACACCAAGAGTCTAAGAGGTTTTAGAGCTATGCTG

JM158

CAGCATAGCTCTAAAACCTCTTAGACTCTTGGTGTAGAAAAAATTTTGTAATCGCACTAT

JM159

TTTGAATGGTCCCAAAACTAAATTTGTTTAGCAGGTAAACCGTGCTTT

JM160

ACAGCATAGCTCTAAAACAGAGCGCAATTAATTATTGCGGATATTCCT

JM161

aaacAAAATTTTTTAGACAAAAATAGTCTACGAGg
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JM162

aaaacCTCGTAGACTATTTTTGTCTAAAAAATTTT

JM163

AAGATTATTTCTTAATAACTAAAAATATGGTATAAAAAATAGTCTACGAGGTTTTAGAGC

JM164

TTATACCATATTTTTAGTTATTAAGAAATAATCTTCATCTAAAATATACTGC

JM169

CGTGAGAAGATTGAAAAAATCTTGACTTTTCGAATTCC

JM170

GGAATTCGAAAAGTCAAGATTTTTTCAATCTTCTCACG

JM171

TGCGCTGGTTGATTTCTTCTTGCGCTTTTT

JM172

ggaattttgaagaagttgtcgataaaggtgcttcagc

JM173

gctgaagcacctttatcgacaacttcttcaaaattcc

JM174

CATCTGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACAACATTGCCGATGATAACT

JM175

GTCTAGCTGAGACAAATAGTGCGATTACAAAATGGGGGAGACAAAAATAGTCTACGAGG

JM176

AGACACCCCGAGTCTACGAGGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACTGCG

JM177

CTCGTAGACTCGGGGTGTCTAAAAAATTTTGTAATCGCACTATTTGTCTC

JM178

CTCGTAGACTATTTTGTGAGAAAAAATTTTGTAATCGCACTATTTGTCTC

JM179

aaacAAAATTTTTTAGACAAAAATAGTCTCATCTg

JM180

aaaacAGATGAGACTATTTTTGTCTAAAAAATTTT

JM181

aaacAAAATTTTTTAGACAAAAATCTGAGACGAGg

JM182

aaaacCTCGTCTCAGATTTTTGTCTAAAAAATTTT

JM183

aaacAAAATTTTTTAGACACCCCGAGTCTACGAGg

JM184

aaaacCTCGTAGACTCGGGGTGTCTAAAAAATTTT

JM185

aaacAAAATTTTTTCTCACAAAATAGTCTACGAGg

JM186

aaaacCTCGTAGACTATTTTGTGAGAAAAAATTTT

JM187

aaacAAAATGGGGGAGACAAAAATAGTCTACGAGg

JM188

aaaacCTCGTAGACTATTTTTGTCTCCCCCATTTT

JM189

aaacCCCCGTTTTTAGACAAAAATAGTCTACGAGg

JM190

aaaacCTCGTAGACTATTTTTGTCTAAAAACGGGG

JM191

ctcggaagctcaaaggtctcGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACTGCG

JM192

gagacctttgagcttccgagactggtctcaGTAATCGCACTATTTGTCTCAGCTAGACTT

JM193

ttacAAAATTTTTTAGACAAAAATAGTCTCATCTg

JM194

ttacAAAATTTTTTAGACAAAAATCTGAGACGAGg

JM195

ttacAAAATTTTTTAGACACCCCGAGTCTACGAGg

JM196

ttacAAAATTTTTTCTCACAAAATAGTCTACGAGg

JM197

ttacAAAATGGGGGAGACAAAAATAGTCTACGAGg

JM198

ttacCCCCGTTTTTAGACAAAAATAGTCTACGAGg

JM199

aaacAAAATTTTTTAGACAAAAATAGTCTACGATg

JM200

aaaacATCGTAGACTATTTTTGTCTAAAAAATTTT

JM201

aaacAAAATTTTTTAGACAAAAATAGTCTACGCGg

JM202

aaaacCGCGTAGACTATTTTTGTCTAAAAAATTTT

JM203

aaacAAAATTTTTTAGACAAAAATAGTCTACTAGg

JM204

aaaacCTAGTAGACTATTTTTGTCTAAAAAATTTT

JM205

aaacAAAATTTTTTAGACAAAAATAGTCTAAGAGg

JM206

aaaacCTCTTAGACTATTTTTGTCTAAAAAATTTT
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JM207

aaacAAAATTTTTTAGACAAAAATAGTCTCCGAGg

JM208

aaaacCTCGGAGACTATTTTTGTCTAAAAAATTTT

JM209

tgagaccagtctcggaagctcaaaggtctcGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACTGCGCTGGTTGATTTCTTCTTGCG

JM210

tgagaccagtctcggaagctcaaaggtctcGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACAACATTGCCGATGATAACTTGAGAAAGAGG

JM211

gagacctttgagcttccgagactggtctcaGTTTTGGGACCATTCAAAACAGCATAGCTCTAAAACCTCGTAGACTATTTTTGTCTAAAAAATTTTGTAATCGCAC

JM212

CATCTgttttagagctatgctgttttgaatggtcccaaaactgagaccagtctcggaagc

JM213

AAAAATATGGTATAACTGAGACAAATAGTGCGATTACAAAATTTTTTAGACAAAAATAG

JM214

CACTATTTGTCTCAGTTATACCATATTTTTAGTTATTAAGAAATAATCTTCATCTAAAAT

JM215

GTGCGATTACAAAATGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACTGCGCTGGT

JM216

GCATAGCTCTAAAACATTTTGTAATCGCACTATTTGTCTCAGCTAGACTTCAGTCTTGAA

JM217

GACTGAAGTCTAGCTGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACTGCGCTGGT

JM218

GCATAGCTCTAAAACAGCTAGACTTCAGTCTTGAAAAGCCCCTGTATTACTGCATTTATT

JM219

ATGCAGTAATACAGGGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACTGCGCTGGT

JM220

GCATAGCTCTAAAACCCTGTATTACTGCATTTATTAAGAGTATTATACCATATTTTTAGT

JM221

AAAATTTTTTAGACAAAAATAGTCTNNNNNGTTTTAGAGCTATGCTGTTTTGAATGGTCC

JM222

AGACTATTTTTGTCTAAAAAATTTTGTAATCGCACTATTTGTC

JM223

tattcttcaactaaaaaacactaaattaataagaaagagccaaacctcgaaag

JM224

tgttgAACTAATGGGTGCgttccaattgaaaccaaagtgctttctcttatctattattc

JM225

ttcaattggaacGCACCCATTAGTTCAACAAACGAAAATTGGATaaagtg

JM226

attaatttagtgttttttagttgaagaataaagaccacattaaaaaatgtggtcttttg

JM227

CAAACGctcgtgTAGAGATAAAAGAGTCCTTTGGATGATTCCAAGG

JM228

TTATTAAGAGTACTAGTTATTATAGGGCATCAAAATATAATCCTTGTCTAAAATAAATTG

JM229

CTATAATAACTAGTACTCTTAATAAATGCAGTAATACAGGGGCTTTTCAAGAC

JM230

TCTTTTATCTCTAcacgagCGTTTGTTGAACTAATGGgtgctttagttg

JM231

GAAGATTCGTAATTTctctgataaatatgaacatgatgagtgatcgttaaatttatact

JM232

CCAAATCACAGAATCctcgtgctataattatactaattttataaggaggaaaaaatatgg

JM233

taattatagcacgagGATTCTGTGATTTGGATCCTTCCAGAAGTC

JM234

tcatatttatcagagAAATTACGAATCTTCTCCTGACGTTTTTTTAAATCTTG

JM235

GATTCGTAATTTcgttagcaaaaacaggtttaagcctcgc

JM236

AAATCACAGAATCcaaaaaatgagtggcaaaatgctagccactc

JM237

actcattttttgGATTCTGTGATTTGGATCCTTCCAGAAGTC

JM238

gtttttgctaacgAAATTACGAATCTTCTCCTGACGTTTTTTTAAATCTtgactg

JM239

aaacGTTTTATATCCAGAATCAGCAAAAGCCGAGg

JM240

aaaacCTCGGCTTTTGCTGATTCTGGATATAAAAC

JM241

aaacAATCTTACTAAAAGAGTTAGAACGAGTTTTg

JM242

aaaacAAAACTCGTTCTAACTCTTTTAGTAAGATT

JM243

aaacTGAGATAATGCCGACTGTACTTTTTACAGTg

JM244

aaaacACTGTAAAAAGTACAGTCGGCATTATCTCA

JM245

ctgaatttggcggtggtacgcaagg

JM246

ccttgcgtaccaccgccaaattcag

JM247

AAATCACAGAATCcaaaaaatgagtggcaaaatgctagcca
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JM248

NNNNNtagCAAAATTTTTTAGACAAAAATAGTC

JM249

NNNNNcagCAAAATTTTTTAGACAAAAATAGTC

JM250

NNNNNctcCAAAATTTTTTAGACAAAAATAGTC

JM251

NNNNNgagCAAAATTTTTTAGACAAAAATAGTC

JM252

NNNNNtccCAAAATTTTTTAGACAAAAATAGTC

JM253

NNNNNcctCAAAATTTTTTAGACAAAAATAGTC

JM254

NNNNNattCAAAATTTTTTAGACAAAAATAGTC

JM255

NNNNNgatCAAAATTTTTTAGACAAAAATAGTC

JM256

NNNNNaaaCAAAATTTTTTAGACAAAAATAGTC

JM257

NNNNNagtCTTTCTCAAGTTATCATCGGC

JM258

NNNNNtagCTTTCTCAAGTTATCATCGGC

JM259

NNNNNcagCTTTCTCAAGTTATCATCGGC

JM260

NNNNNctcCTTTCTCAAGTTATCATCGGC

JM261

NNNNNgagCTTTCTCAAGTTATCATCGGC

JM262

NNNNNtccCTTTCTCAAGTTATCATCGGC

JM263

NNNNNcctCTTTCTCAAGTTATCATCGGC

JM264

NNNNNattCTTTCTCAAGTTATCATCGGC

JM265

NNNNNgatCTTTCTCAAGTTATCATCGGC

JM266

NNNNNaaaCTTTCTCAAGTTATCATCGGC

JM267

CATCTGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACAGTGCCGAGGAAAAATTAG

JM268

AGACAAAAATAGTCTNNNNNGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACAGTG

JM269

AGACTATTTTTGTCTAAAAAATTTTGTAATCGCACTATTTGTCTCAGCTAGACTTCAG

JM270

CATCTGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACCTCGTAGACTATTTTTGTCTAAAAAATTTTGTTAATACCAGCAGTCGGATACCTTCC

JM271

CAAAACAGCATAGCTCTAAAACAGATGAGACTATTTTTGTCTAAAAAATTTTGTAATCGC

JM272

GATTATTTCTTAATAACTAAAAATATGGTATAAGTTAATACCAGCAGTCGGATACCTTCC

JM273

TTATACCATATTTTTAGTTATTAAGAAATAATCTTCATCTAAAATATACTGCGG

JM274

TTGGGACCATTCAAAACAGCATAGCTCTAAAACAACATTGCCGATGATAACTTGAGAAAG

JM275

GCTGTTTTGAATGGTCCCAAAACCTCGTAGACTATTTTTGTCTAAAAAATTTTGTAATCG

JM276

GGAGAAGATTCGTAATTTtttatactgcaatcggatgcgat

JM277

CCAAATCACAGAATCatgttcatatttatcagagctcg

JM278

gataaatatgaacatGATTCTGTGATTTGGATCCTTCCAGAAGTC

JM279

cgattgcagtataaaAAATTACGAATCTTCTCCTGACGTTTTTTTAAATCTTG

JM280

CTTGGTATTTCACAAATTGTAACGCTTTAATACGC

JM281

ccttaacaatcccaaaacttgtcgaatctcactatcaatcatttctccaccattag

JM282

ctaatggtggagaaatgattgatagtgagattcgacaagttttgggattgttaagg

JM283

gtttgataaaatattctgcaaaaaaggggacggtcggcttaatagctcacgctatgcc

JM284

ggcatagcgtgagctattaagccgaccgtccccttttttgcagaatattttatcaaac

JM285

CCCCGAGTCTACGAGGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACTGCGCTGGTTGATT

JM286

GCATAGCTCTAAAACCTCGTAGACTCGGGGTGTCTAAAAAATTTTGTAATCGCAC

JM287

CTCACAAAATAGTCTACGAGGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACTGCGCTGGTTGATT

JM288

GCTCTAAAACCTCGTAGACTATTTTGTGAGAAAAAATTTTGTAATCGCACTATTTGTCTC
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JM289

GGGGGAGACAAAAATAGTCTACGAGGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACTGCGCTGGTTGATT

JM290

AAAACCTCGTAGACTATTTTTGTCTCCCCCATTTTGTAATCGCACTATTTGTCTCAGCTA

JM291

CCCCGTTTTTAGACAAAAATAGTCTACGAGGTTTTAGAGC

JM292

CTCGTAGACTATTTTTGTCTAAAAACGGGGGTAATCGCACTATTTGTCTCAGCTAGAC

JM293

GTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACTGCGCTGGTTGATTTCTTCTTGCG

JM294

GGACCATTCAAAACAGCATAGCTCTAAAACATTTTGTAATCGCACTATTTGTCTCAGCTA

JM295

GGACCATTCAAAACAGCATAGCTCTAAAACAGCTAGACTTCAGTCTTGAAAAGCCCCTGT

JM296

GGACCATTCAAAACAGCATAGCTCTAAAACCCTGTATTACTGCATTTATTAAGAGTATTA

JM297

TATTTCTTAATAACTAAAAATATGGTATAAGATTAAGCCATATGGGGTTAAGCAAGG

JM298

GCTTAATCTTATACCATATTTTTAGTTATTAAGAAATAATCTTCATCTAAAATATACTGC

JM299

GGCAAAAGAAGAGTAGTGTGATGGAACAAACggtcataacctgaaggaagatctggatcc

JM300

GATATATACTCTTGTAAACTAGCCACTTCATCCatctgtgccagttcgtaatgtctggtc

JM301

acattacgaactggcacagatGGATGAAGTGGCTAGTTTACAAGAGTATATATCATTGAC

JM302

ggatccagatcttccttcaggttatgaccGTTTGTTCCATCACACTACTCTTCTTTTGCC

JM303

caggtatgaaaacaagcttaggcatggg

JM304

gctgaaatttaattgtcaaaaaatgtgacattcggtcggcttaatagctcacgctatgcc

JM305

ggcatagcgtgagctattaagccgaccgaatgtcacattttttgacaattaaatttcagc

JM306

aatcccaaaacttgtcgaattaaatttaattacactctaaaattcgtgaatttttaatgg

JM307

aaattcacgaattttagagtgtaattaaatttaattcgacaagttttgggattgttaagg

JM308

gaacGTATTTTAGTTAATGGTGATTCAATGGAACCTATG

JM309

tttaCATAGGTTCCATTGAATCACCATTAACTAAAATAC

JM310

CCATTAGTTCAACAAACGCTCGTGAGCTTACTATGCCATTATTaataacttagcc

JM311

CCAATTTTCGTTTTGTCACTTTGCTTGATATATGAGAATTATTTAACC

JM312

CAAGCAAAGTGACAAAACGAAAATTGGATAAAGTGGGATATTTTTAAAATATAT

JM313

ggctaagttattAATAATGGCATAGTAAGCTCACGAGCGTTTGTTGAACTAATGG

JM314

CGGATTTAGAGATACCAAATTAATATAGTCTTCGC

JM315

TAGCAAAGGCTTTAAACGTTAACGAAGC

JM316

GCGCTCTGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACTAAATTTGTTTAGCAGG

JM317

ATAGCTCTAAAACAGAGCGCAATTAATTATTGCGGATATTCCT

JM318

TTTGAATGGTCCCAAAACTAAATTTGTTTAGCAGGTAAACCGTGCTTT

JM319

ACAGCATAGCTCTAAAACAGAGCGCAATTAATTATTGCGGATATTCCT

JM320

aaacGTGTTCTCTTCAATCCATTCATCTATTGCTg

JM321

aaaacAGCAATAGATGAATGGATTGAAGAGAACAC

JM322

aaacCGAATATACAGGAAGAATACACGATGTTGTg

JM323

aaaacACAACATCGTGTATTCTTCCTGTATATTCG

JM324

aaacGTTTGTGTATCAGCCATATTTTGCTTTAATg

JM325

aaaacATTAAAGCAAAATATGGCTGATACACAAAC

JM326

GTGCGATTACAAAATTTTTTAGACAAAAATAGTCTNNNNNGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACAGTGCCGAGG

JM327

TTTTTAGACAAAAATAGTCTNNNNNGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACAGTGCCGAGGAAAAATTAGGTGCGCTTGGC

JM328

cgagctctgataaatatgaacatGGATGAAGTGGCTAGTTTACAAGAGTATATATCATTG

JM329

CACTTCATCCatgttcatatttatcagagctcgtgctataattatactaattttataagg
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JM330

TGTCATGATAATAATGGTTTCTTAGGATTCTGTGATTTGGATCCTTCCAGAAGTC

JM331

CGAAAAGTGCCACCTGACGTAAATTACGAATCTTCTCCTGACGTTTTTTTAAATCTTG

JM332

CAAGATTTAAAAAAACGTCAGGAGAAGATTCGTAATTTACGTCAGGTGGCACTTTTCG

JM333

CTGGAAGGATCCAAATCACAGAATCCTAAGAAACCATTATTATCATGACATTAACC

JM334

GGTTTCTTAGGATTCTGTGATTTGGATCCTTCCAGAAGTCTTTTTCTTGCACTG

JM335

AAATTACGAATCTTCTCCTGACGTTTTTTTAAATCTTGACTGTTCATTC

JM336

GAAGGAGATATACCATGGGCGCCAGCGTTAATAGATCTTGTACAGCAAGG

JM337

CAGCCGGATCAAGTATACATTTGTTCTTAAAGCATTTTTTCCCATAAAAACAACC

JM338

TTAAGAACAAATGTATACTTGATCCGGCTGCTAACAAAGCCC

JM339

TAACGCTGGCGCCCATGGTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGG

JM340

GCGTTGCGCCATACTTGCACATTATCAAACAAAATCAATTATTAAAATAGATGTTTAAG

JM341

GCGGTGGCAGCAGCCTAGGCCATCCCCTAGAAATTAATCAATGCG

JM342

CGCATTGATTAATTTCTAGGGGATGGCCTAGGCTGCTGCCACCGC

JM343

GATTTTGTTTGATAATGTGCAAGTATGGCGCAACGCAATTAATGTAAGTTAGCTC

JM344

AAAATTTTTTAGACAAAAATctgagcatctGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACTGCGCTGGTTG

JM345

agatgctcagATTTTTGTCTAAAAAATTTTGTAATCGCACTATTTGTCTCAGC

JM346

AAAATTTTTTctcacccccgAGTCTACGAGGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACTGCGCTGGTTG

JM347

CTCGTAGACTcgggggtgagAAAAAATTTTGTAATCGCACTATTTGTCTCAGCTAGACTT

JM348

CccccggggggAGACAAAAATAGTCTACGAGGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACTGCGCTGGTTG

JM349

TCGTAGACTATTTTTGTCTccccccggggGTAATCGCACTATTTGTCTCAGCTAGACTTC

JM350

gaccagacattacgaactggcacagatGATTCTGTGATTTGGATCCTTCCAGAAGTC

JM351

gatcttccttcaggttatgaccAAATTACGAATCTTCTCCTGACGTTTTTTTAAATCTTG

JM352

TAAAAAAACGTCAGGAGAAGATTCGTAATTTggtcataacctgaaggaagatctggatcc

JM353

GACTTCTGGAAGGATCCAAATCACAGAATCatctgtgccagttcgtaatgtctggtc

JM354

AAAATTTTTTAGACAAAAATctgagcatctGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACTGCGCTGGTTGATTTCTTCTTGCGCTTTTT

JM355

GAGCTAACTTACATTAATTGCGTTGCGCacctctggtgaaggagttggc

JM356

GCGGTGGCAGCAGCCTAGGgtttaaggttggtgtcttttttacctgtttgaaaacaaag

JM357

ctttgttttcaaacaggtaaaaaagacaccaaccttaaacCCTAGGCTGCTGCCACCGC

JM358

gccaactccttcaccagaggtGCGCAACGCAATTAATGTAAGTTAGCTC

JM359

aaacGTGTTCTCTTCAATCCATTCATCTATTGCTg

JM360

aaaacAGCAATAGATGAATGGATTGAAGAGAACAC

JM361

aaacGTTTGTGTATCAGCCATATTTTGCTTTAATg

JM362

aaaacATTAAAGCAAAATATGGCTGATACACAAAC

JM363

aaactcgcttcttctttactctcTAGGGATAACAg

JM364

aaaacTGTTATCCCTAgagagtaaagaagaagcga

JM365

aaacagaagctatatcctaaaatTAGGGATAACAg

JM366

aaaacTGTTATCCCTAattttaggatatagcttct

JM367

GTTAAGTATAAGAAGGAGATATACATatgtatctgctggtgagctttgatct

JM368

CAGCAGttaaataaaaatcagtttcggttctttgttcacgg

JM369

gaaccgaaactgatttttatttaaCTGCTGCCACCGCTGA

JM370

acatATGTATATCTCCTTCTTATACTTAACTAATATACTAAGATGGGG
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JM371

TCACCACAGCatgaaagatgtgatctatgtggagaatcattattttgtg

JM372

TTCTGTTCGAttaattgccaacttcaatcatcttcggc

JM373

tgattgaagttggcaattaaTCGAACAGAAAGTAATCGTATTGTACACGG

JM374

acatagatcacatctttcatGCTGTGGTGATGATGGTGATGG

JM375

TAAGAAGGAGATATACCATGaaagatgtgatctatgtggagaatcattattttgtg

JM376

tcacatctttCATGGTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGG

JM377

NNNNNatgAGTGCCGAGGAAAAATTAGGTGCGCTTGGC

JM378

NNNNNatgAAAGCACGGTTTACCTGCTAAACAAATTTA

JM379

NNNNNtacAGTGCCGAGGAAAAATTAGGTGCGCTTGGC

JM380

NNNNNtacAAAGCACGGTTTACCTGCTAAACAAATTTA

JM381

NNNNNctaAGTGCCGAGGAAAAATTAGGTGCGCTTGGC

JM382

NNNNNctaAAAGCACGGTTTACCTGCTAAACAAATTTA

JM383

CGCAGTATATTTTAGATGAAGATTATTTCTTAATAACTAAAAATATGGTATAA

JM384

AAAAAGCGCAAGAAGAAATCAACCAGCGCA

JM385

AGAAATAATCTTCATCTAAAATATACTGCGGAAAATCATATAGTTC

JM386

aaaacctacagaaaacactaaattaataagaaagagccaaacctcgaaag

JM387

ttaaaagctgttccaattgaaaccaaagtgctttctcttatctattattc

JM388

taagagaaagcactttggtttcaattggaacagcttttaaaaagcaaatatgagcc

JM389

ggctctttcttattaatttagtgttttctgtaggtttttaggcataaaactatatg

JM390

aaacTgtggagaggCAATCCATTCATCTATTGCTg

JM391

aaaacAGCAATAGATGAATGGATTGcctctccacA

JM392

aaacTgggtgtgcgCAGCCATATTTTGCTTTAATg

JM393

aaaacATTAAAGCAAAATATGGCTGcgcacacccA

JM394

ATGCGTCCGGCGTAGA

JM395

GATTATGCGGCCGTGTACAA

JM396

cctttgatattaatgagaaaaaactgctgctgaatgtg

JM397

gaacATGTCACCTAAGTCAACACCATCATTTTTTATTCTg

JM398

cgatcAGAATAAAAAATGATGGTGTTGACTTAGGTGACAT

JM399

aaacGTCACGAGGTTATTATGTACGAGTTAATCAg

JM400

aaaacTGATTAACTCGTACATAATAACCTCGTGAC

JM401

aaacTTTGACGCAATAGGTGCTATAACTAAAATGg

JM402

aaaacCATTTTAGTTATAGCACCTATTGCGTCAAA

JM403

aaacATGTAAACTTGTAATTAATCCGTAAGCCATg

JM404

aaaacATGGCTTACGGATTAATTACAAGTTTACAT

JM405

aaacTTATACTCTTGGTAAATCCTAGAATTGTTAg

JM406

aaaacTAACAATTCTAGGATTTACCAAGAGTATAA

JM407

aaacGTACATAATAACCTCGTGACCTTTTTCGTTg

JM408

aaaacAACGAAAAAGGTCACGAGGTTATTATGTAC

JM409

catatagttttatgcctaaaaacctacagatagtttaaaatcatttgttcaaaaat

JM410

ggctcatatttgctttttaaaagctcactgtgaattattatcaaaacc

JM411

ggctcatatttgctttttaaaagcttttagtccagctctaagatttg
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JM412

CAAAATTTTTTAGACAAAAATAGTCTNNNNNGTTTTAGAGCTATGCTGTTTTGAATGGTC

JM413

AGTGCCGAGGAAAAATTAGGTGCGCTTGGCGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACTGCGCTGGTTGATTTCTTCTTGCGCTTTTT

JM414

GCCAAGCGCACCTAATTTTTCCTCGGCACTTTATACCATATTTTTAGTTATTAAGAAATA

JM415

TCAATGAGTGGTATCCAAGACGAAAACTTATTTTGTTATCACAATTTTCGGTTGACATC

JM416

GATGTCAACCGAAAATTGTGATAACAAAATAAGTTTTCGTCTTGGATACCACTCATTGA

JM417

cgagctctgataaatatgaacatgaatatcctaaatcagttgtttcattttagttacc

JM418

atcgcatccgattgcagtataaatttagtccagctctaagatttgaggtgaag

JM419

cttcacctcaaatcttagagctggactaaatttatactgcaatcggatgcgat

JM420

ggtaactaaaatgaaacaactgatttaggatattcatgttcatatttatcagagctcg

JM421

catatagttttatgcctaaaaacctacagaATCACAAGCTGATGTATTATTTTTG

JM422

ggctcatatttgctttttaaaagctGTCCCTTCTCACATTTCAATACTAG

JM423

cgagctctgataaatatgaacatATCACAAGCTGATGTATTATTTTTG

JM424

CTCGTAGGATATCTTTTCTACCAGA

JM425

TCTGGTAGAAAAGATATCCTACGAGgtttttgtactctcaagatttaagtaactgtacaacatgatgatgaagtatcgtcatctactaac

JM426

CAAAAATAATACATCAGCTTGTGATatgttcatatttatcagagctcg

JM427

agttttatgcctaaaaacctacagagaatatcctaaatcagttgtttcattttagttacc

JM428

ctcaaatgatttttgagattttcatacc

JM429

ggtatgaaaatctcaaaaatcatttgagGTTTTAGAGCTGTGTTGTTTCGAATGGTTCCAAAACGGTGAAAAAGGTTCACTGTACGAGTACTTA

JM430

ggtttcggaatgaagtgaataacgttgtttag

JM431

cagcttatcgttcagaagccttaagg

JM432

gcaaagcaaatagttccatttttggaaaagg

JM433

ggatgatgcgtggtctttccg

JM434

gtcaaaattcctcatgtatcgtcacgac

JM435

ggtaagaacagatgtcctaggaaatcagc

JM436

gagagggacatgctgccaag

JM437

gtgagacttttggcggttactgaaaag

JM438

gaccatcttcttttacaaacaacagagaagtatc

JM439

ctgatgaaaaacttttacagaaatttttagaaagtaagg

JM440

gaaaattttaatttgcatgtaactgggcagtg

JM441

gtcgttaaaccgtgtgctctacgacc

JM442

GCTATAACTAAAATGgttttagagctatgctgttttgaatggtcccaaaacttcagcaca

JM443

ACCTATTGCGTCAAAgttttgggaccattcaaaacagcatagctctaaaacctcgtagac

JM444

aaacTGTAATTGTCATACTTGATAAGTCTACTATg

JM445

aaaacATAGTAGACTTATCAAGTATGACAATTACA

JM446

aaaaatcatacgaggtttttgtactctcaagatttaagtaactgtacaacatgatgatga

JM447

aaaaacctcgtatgatttttgagattttcatacccacatagtgattataa

JM448

AGATATCCTttGAGgtttttgtactctcaagatttaagtaactgtacaacatgatgatga

JM449

aaaaacCTCaaAGGATATCTTTTCTACCAGATTTCGTAATCGCACTATTAATC

JM450

gtttttgtactctcaagatttaagtaactgtacaacagcttttaaaaagcaaatatgagc

JM451

gttgtacagttacttaaatcttgagagtacaaaaacctcaaatgatttttgagattttca

JM452

AGAGCTGTGTTGTTTCGAATGGTTCCAAAACTTTTGTTATCACAATTTTCGGTTGACATC

91

JM453

ACCATTCGAAACAACACAGCTCTAAAACCTCGTAGGATATCTTTTCTACCAGATTTCGTA

JM454

gataaatatgaacatTTTGGTAATAGGCATTATTACAAATG

JM455

ttgcagtataaaCTACACCCTGTAGACTTTTTAATAAAATTG

JM456

AAAGTCTACAGGGTGTAGtttatactgcaatcggatgcgat

JM457

ATGCCTATTACCAAAatgttcatatttatcagagctcg

JM458

GTTTCAACTTATTATAAGAAGCGGaacttttcactggagttgtcc

JM459

ACCTCCCTTATAACCGCTTCTTATTTGTATAGTTCATCCATGCC

JM460

ATACAAATAAGAAGCGGTTATAAGGGAGGTTTGTTAGTTGATAGC

JM461

aaagttCCGCTTCTTATAATAAGTTGAAACTTCCGTCTATAG

JM462

aaacCGCTATAGACGGAAGTTTCAACTTATTATAg

JM463

aaaacTATAATAAGTTGAAACTTCCGTCTATAGCG

JM464

GTTGGTCACAGATATGGAGTACAATCACTAATTTTG

JM465

TCACGCATTGATGACATGAACGCTATAG

JM466

cctgtccttttaccagacaaccattacc

JM467

CTTTGTCGTTTGAAACAACCGAACTACC

JM468

aaacGCTATAGACGGAAGTTTCAACTTATTATAAg

JM469

aaaacTTATAATAAGTTGAAACTTCCGTCTATAGC

JM470

aaacATAGACGGAAGTTTCAACTTATTATAAGGGg

JM471

aaaacCCCTTATAATAAGTTGAAACTTCCGTCTAT

JM472

tatgtgggtatgaaaatctcaaaa

JM473

gttacttaaatcttgagagtacaaaaacA

JM474

gttacttaaatcttgagagtacaaaaacT

JM475

gttacttaaatcttgagagtacaaaaacG

JM476

TAGTGCGATTACGAAATCTGG

JM477

GAAACAACACAGCTCTAAAACa

JM478

GAAACAACACAGCTCTAAAACt

JM479

GAAACAACACAGCTCTAAAACg

JM480

gggattattaaatgagtgacttagttcatatcatcaaaaatgaggg

JM481

ccctcatttttgatgatatgaactaagtcactcatttaataatccc

JM482

gaagaaatgacttggagagttaaattccactgcccag

JM483

ctgggcagtggaatttaactctccaagtcatttcttc

JM484

atgaaaatctcaaaaatcatttgagGTTTTAgtactctcaagatttaagTGGTTCCAAAACatgatgatgaagtatcgtcatctactaac

JM485

ctcaaatgatttttgagattttcatacccac

JM486

TCTGGTAGAAAAGATATCCTACGAGgtttttGAGCTGTGTTGTTTCGAAtaactgtacaacGGTGAAAAAGGTTCACTGTACGAGTACTTA

JM487

CTCGTAGGATATCTTTTCTACCAGATTTCGTAATC

JM488

atgatgaagtatcgtcatctactaacCCAGAAAACAagtcgttgaggcagagagta

JM489

TCTGGgttagtagatgacgatacttcatcatcatgtttacgtcctgttgaatctttg

JM490

GGTGAAAAAGGTTCACTGTACGAGTACTTATGGCGagtcgttgaggcagagagta

JM491

ATAAGTACTCGTACAGTGAACCTTTTTCACCgtttacgtcctgttgaatctttg

JM492

atgatgatgaagtatcgtcatctactaacGTTTTAgtactctcaagatttaagTGGTTCCAAAACcttcacctcaaatcttagagctggactaaa

JM493

gttagtagatgacgatacttcatcatcatg
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JM494

GGTGAAAAAGGTTCACTGTACGAGTACTTAgtttttGAGCTGTGTTGTTTCGAAtaactgtacaacTCAATGAGTGGTATCCAAGACGAAAACTTA

JM495

TAAGTACTCGTACAGTGAACCTTTTTCACC

JM496

catgatgatgaagtatcgtcatctactaac

JM497

GGAACCacttaaatcttgcagaagctacTaagataaggcttcatgccg

JM498

AgtagcttctgcaagatttaagtGGTTCCgtaaggcgtcccttacactattattatag

JM499

GTTGTTTCGAATaacTTtacACCACAATTATTATTATATAGTTTTATAACTAATATGTC

JM500

GGTgtaAAgttATTCGAAACAACACAGCGAGTaAAAATAAGGCTTAGTCCGTACTCAAC

JM501

GAGCTAACTTACATTAATTGCGTTGCGCTTAAATATTTACCTTTTTAATCAATGG

JM502

GCGGTGGCAGCAGCCTAGGGGGTTATATGGTGGTTTATCC

JM503

GGATAAACCACCATATAACCCCCTAGGCTGCTGCCACCGC

JM504

CCATTGATTAAAAAGGTAAATATTTAAGCGCAACGCAATTAATGTAAGTTAGCTC

JM505

GATTACGAAATCTGGTAGAAAAGATATCCTttGAGGTTTTAGAGCTGTGTTGTTTCGAATGGTTCCAAAACGGTGAAAAAGGTTCACTGTACGAGTACTTA

JM506

AGGATATCTTTTCTACCAGATTTCGTAATCGC

JM507

ATCATTAATTAATAATAGGTTATGTTTAGAGATCGATACCCACCCCGAAGAAAAGGGGACGAGAACACGTATGCCGAAGTATATAAATCATCAGTACAAAG

JM508

TCTAAACATAACCTATTATTAATTAATGATTTTTTAAGCCAGTCAC

JM509

TGCTGAAGAGAGGAAAGCGTATCG

JM510

CGATACGCTTTCCTCTCTTCAGCA

JM511

GCTAGTAAACCGCCTCGCGCagcttttaaaaagcaaatatgagcc

JM512

ggctcatatttgctttttaaaagctGCGCGAGGCGGTTTACTAGC

JM513

TCTGGTAGAAAAGATATCCTACGAGgtttttGAGCTGTGTTGTTTCGAATGGTTCCAAAACGGTGAAAAAGGTTCACTGTACGAGTACTTA

JM514

TCTGGTAGAAAAGATATCCTACGAGGTTTTAGAGCTGTGTTGTTTCGAAtaactgtacaacGGTGAAAAAGGTTCACTGTACGAGTACTTA

JM523

GCGGATAACAATTAAGCTTGTACAATAAAAGGAGAAATGTTATTTGCC

JM524

CCTAGGAGCTCTCGAGATCTACTTCCTCCTCTATCATAATAAATTTAAA

JM525

TTTAAATTTATTATGATAGAGGAGGAAGTAGATCTCGAGAGCTCCTAGG

JM526

GGCAAATAACATTTCTCCTTTTATTGTACAAGCTTAATTGTTATCCGC

JM527

tgGTCTTCgtctcggaagctcaaGAAGACcGTTTTAGAGCTGTGTTGTTTCGAATGGTTCCAAAACGATTGTGCCCGCTAGTAAA

JM528

gGTCTTCttgagcttccgagacGAAGACcaGTTTTGGAACCATTCGAAACAACACAGCTCTAAAACCTCGTGGACCAATTTTCG

JM529

GATTGAGAAAATATTGACTTTCCGTATTCCCTA

JM530

TAGGGAATACGGAAAGTCAATATTTTCTCAATC

JM531

atgaaaatctcaaaaatcatACgagGTTTTAgtactctcaagatttaagTGGTTCCAAAACatgatgatgaagtatcgtcatctactaac

JM532

ctcGTatgatttttgagattttcatacccac

JM533

TCTGGTAGAAAAGATATCCTttGAGgtttttGAGCTGTGTTGTTTCGAAtaactgtacaacGGTGAAAAAGGTTCACTGTACGAGTACTTA

JM534

CTCaaAGGATATCTTTTCTACCAGATTTCGTAATC

JM535

gagagggacatgctgccAGAgtctactttaatgagctctttggtaaac

JM536

gtttaccaaagagctcattaaagtagacTCTggcagcatgtccctctc

JM537

caaacatctacaatctgtctaaatg

JM538

GTGAGGGTCACTCTGCCaagATTTATTTTAATACGCTTTTCGGTA

JM539

TACCGAAAAGCGTATTAAAATAAATcttGGCAGAGTGACCCTCAC

JM540

AAACctcgtTGGTTGATTTCTTCTTGCGCTTTTTg

JM541

aaaacAAAAAGCGCAAGAAGAAATCAACCAacgag

JM542

AAACagatgTGGTTGATTTCTTCTTGCGCTTTTTg
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JM543

aaaacAAAAAGCGCAAGAAGAAATCAACCAcatct

JM544

tggttgacgacttgatggCgccatttagacagattgtagatg

JM545

catctacaatctgtctaaatggcGccatcaagtcgtcaacca

JM546

ATTTAACCTTGCTAGTGATATTATGGcGCCATTTAGGCCAATTATAGA

JM547

TCTATAATTGGCCTAAATGGCgCCATAATATCACTAGCAAGGTTAAAT

JM548

aatcatttgaggtttttgtactctcaagatttaagtaactgtacaacatgatgatgaagtatcgtcatctacta

JM549

tagtagatgacgatacttcatcatcatgttgtacagttacttaaatcttgagagtacaaaaacctcaaatgatt

JM550

TATCCTACGAGGTTTTAGAGCTGTGTTGTTTCGAATGGTTCCAAAACGGTGAAAAAGGTTCACTGTACGAGTAC

JM551

GTACTCGTACAGTGAACCTTTTTCACCGTTTTGGAACCATTCGAAACAACACAGCTCTAAAACCTCGTAGGATA

JM552

tagtataataaagcattttaacattatacttttgataatcgtttatcgtc

JM553

gactaggttgtctcagcatttttgtcaataaataaggtgtcacagt

JM554

actgtgacaccttatttattgacaaaaatgctgagacaacctagtc

JM555

gattatcaaaagtataatgttaaaatgctttattatactaacgttatata

JM556

atttcttttttcttgtaaaaaaagaaagttcttaaaggttttatagtttt

JM557

CTCTATCAAATCCTTATAATCTACTCTCTAACAAAATGATTATCCCATTCAA

JM558

TTGAATGGGATAATCATTTTGTTAGAGAGTAGATTATAAGGATTTGATAGAG

JM559

aaacctttaagaactttctttttttacaagaaaaaagaaattagataaat

JM560

catatagttttatgcctaaaaacctacagaTAGAGATAAAAGAGTCCTTTGGATG

JM561

CAAAAATAATACATCAGCTTGTGATAACTTTGTATATTCCAAGATTTGATAAA

JM562

TTTATCAAATCTTGGAATATACAAAGTTATCACAAGCTGATGTATTATTTTTG

JM563

CATCCAAAGGACTCTTTTATCTCTAtctgtaggtttttaggcataaaactatatg

JM564

cattacgaactggcacagattagtttaaaatcatttgttcaaaaataaaatcc

JM565

ggattttatttttgaacaaatgattttaaactaatctgtgccagttcgtaatg

JM566

ggtccattcactattctcattcccttttcagataattttagatttgcttttcta

JM567

tagaaaagcaaatctaaaattatctgaaaagggaatgagaatagtgaatggacc

JM568

CTATCAAATCCTTATAATCTACTCTCTAACAAAATGATTATCCCATTCAACTTCA

JM569

cattacgaactggcacagatTAGAGATAAAAGAGTCCTTTGGATG

JM570

CATCCAAAGGACTCTTTTATCTCTAatctgtgccagttcgtaatg

JM571

ggtccattcactattctcattcccttttcagataattttagatttgcttttcta

JM572

tagaaaagcaaatctaaaattatctgaaaagggaatgagaatagtgaatggacc

JM573

CAATCGTATGACAAATTATGATaaGTACTTGCCAAATCAAAAAGTTCTTC

JM574

CAAATAATTCCTTTTTAAAAGATTTTAATTAATTATATTATACC

JM575

GGTATAATATAATTAATTAAAATCTTTTAAAAAGGAATTATTTG

JM576

TTTTGATTTGGCAAGTACttATCATAATTTGTCATACGATTGATAAAAGC

JM577

GATTCTGTGATTTGGATCCTTCCAGAAGTCTTTTTCTTGC

JM578

GCAAGAAAAAGACTTCTGGAAGGATCCAAATCACAGAATC

JM579

actggcacagatAAACACTAAATTAATAAGAAAGAGCCAAACCTCGAAAG

JM580

ggatccagatcttccttcaggttatgaccGCGCGAGGCGGTTTACTAGC

JM581

GCTAGTAAACCGCCTCGCGCggtcataacctgaaggaagatctggatcc

JM582

TCTTTCTTATTAATTTAGTGTTTatctgtgccagttcgtaatgtctggtc
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Supplementary DNA sequences (5’-3’)
>pJM37gw (Swap spacers 2 and 4)
GGTCTCAAAACTGCGCTGGTTGATTTCTTCTTGCGCTTTTTGTTTTAGAGCTA
TGCTGTTTTGAATGGTCCCAAAACAGTGCCGAGGAAAAATTAGGTGCGCTTG
GCGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACAGGAATATCCGCAA
TAATTAATTGCGCTCTGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACT
TATATGAACATAACTCAATTTGTAAAAAAGTTTTAGAGCTATGCTGTTTTGAAT
GGTCCCAAAACTAAATTTGTTTAGCAGGTAAACCGTGCTTTGTTTTAGAGCTA
TGCTGTTTTGAATGGTCCCAAAACTTCAGCACACTGAGACTTGTTGAGTTCC
ATGTTTTAGAGACC
>pJM73gw (LAS Duplication in Spacer 4)
GGTCTCaaaacTGCGCTGGTTGATTTCTTCTTGCGCTTTTTGTTTTAGAGCTAT
GCTGTTTTGAATGGTCCCAAAACTTATATGAACATAACTCAATTTGTAAAAAA
GTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACAGGAATATCCGCAATA
ATTAATTGCGCTCTGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACAAA
ATTTTTTAGACAAAAATAGTCTACGAGGTTTTAGAGCTATGCTGTTTTGAATG
GTCCCAAAACTAAATTTGTTTAGCAGGTAAACCGTGCTTTGTTTTAGAGCTAT
GCTGTTTTGAATGGTCCCAAAACTTCAGCACACTGAGACTTGTTGAGTTCCA
Tgttttagagacc
>pJM87gw (Position 5 phage targeting spacer)
GGTCTCAAAACTGCGCTGGTTGATTTCTTCTTGCGCTTTTTGTTTTAGAGCTA
TGCTGTTTTGAATGGTCCCAAAACTTATATGAACATAACTCAATTTGTAAAAA
AGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACAGGAATATCCGCAAT
AATTAATTGCGCTCTGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACAG
TGCCGAGGAAAAATTAGGTGCGCTTGGCGTTTTAGAGCTATGCTGTTTTGAA
TGGTCCCAAAACGTGTTCTCTTCAATCCATTCATCTATTGCTGTTTTAGAGCT
ATGCTGTTTTGAATGGTCCCAAAACTAAATTTGTTTAGCAGGTAAACCGTGCT
TTGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACTTCAGCACACTGAGA
CTTGTTGAGTTCCATGTTTTAGAGACC
>pJM258
aaaatgctgagacaacctagtctctcacttgttgattcagtaatattgaatatcctaaatcagttgtttcattttagttac
cgtataagatatttacaaaaatctgatgaaaaacttttacagaaatttttagaaagtaaggattgacaagaacagt
tattgattttataatcactatgtgggtatgaaaatctcaaaaatcatttgaggtttttgtactctcaagatttaagtaactg
tacaacATGAAAATCACAGGACAAGCGCAATTTACTgtttttgtactctcaagatttaagtaact
gtacaacTGATATTGTAGAATACTTCTTTAACTATTAgtttttgtactctcaagatttaagtaact
gtacaacggtcataacctgaaggaagatctggatcctaatgaattcatctgcaggggcccatcagtctgacgac
caagagagccataaacaccaatagccttaacatcatccccatatttatccaatattcgttccttaatttcatgaaca
atcttcattctttcttctctagtcattattattggtccattcactattctcattcc
>pJM259
95

aaaatgctgagacaacctagtctctcacttgttgattcagtaatattgaatatcctaaatcagttgtttcattttagttac
cgtataagatatttacaaaaatctgatgaaaaacttttacagaaatttttagaaagtaaggattgacaagaacagt
tattgattttataatcactatgtgggtatgaaaatctcaaaaatcatttgaggtttttgtactctcaagatttaagtaactg
tacaacACACAATGTATACATCATGGCAGACAAACAgtttttgtactctcaagatttaagtaact
gtacaacTAGGGTCTAATCGAAAAGCAGGCGTCTAGAgtttttgtactctcaagatttaagtaa
ctgtacaacTCTTAAACAAGCCACAATTCGATCAGCCAAgtttttgtactctcaagatttaagta
actgtacaactgagaccagtctcggaagctcaaaggtctcgtttttgtactctcaagatttaagtaactgtacaacA
TGAAAATCACAGGACAAGCGCAATTTACTgtttttgtactctcaagatttaagtaactgtacaac
TGATATTGTAGAATACTTCTTTAACTATTAgtttttgtactctcaagatttaagtaactgtacaac
ggtcataacctgaaggaagatctggatcctaatgaattcatctgcaggggcccatcagtctgacgaccaagaga
gccataaacaccaatagccttaacatcatccccatatttatccaatattcgttccttaatttcatgaacaatcttcattct
ttcttctctagtcattattattggtccattcactattctcattcc
>pJM261
TTAGAGAGTAGATTATAAGGATTTGATAGAGGAGGAATTAAGTTGCTTGACA
TATGATTATTAAGAAATAATCTAATATGGTGACAGTCACATCTTGTCTAAAAC
GTTGATATATAAGGATTTTTAAGGTATAATAAATATAAAAATGGAATTATTTTG
AAGCTGAAGTCATGCTGAGATTAATAGTGCGATTACGAAATCTGGTAGAAAA
GATATCCTACGAGGTTTTAGAGCTGTGTTGTTTCGAATGGTTCCAAAACTTAA
TACAGGTTTTTACAAAAGCTTTACCATGTTTTAGAGCTGTGTTGTTTCGAATG
GTTCCAAAACCAGAACACGCAAGAGTGCAAACGTTAGCTCGTTTTAGAGCTG
TGTTGTTTCGAATGGTTCCAAAACggtcataacctgaaggaagatctggatcctaatgaattcat
ctgcaggggcccatcagtctgacgaccaagagagccataaacaccaatagccttaacatcatccccatatttat
ccaatattcgttccttaatttcatgaacaatcttcattctttcttctctagtcattattattggtccattcactattctcattcc
>pJM262
TTAGAGAGTAGATTATAAGGATTTGATAGAGGAGGAATTAAGTTGCTTGACA
TATGATTATTAAGAAATAATCTAATATGGTGACAGTCACATCTTGTCTAAAAC
GTTGATATATAAGGATTTTTAAGGTATAATAAATATAAAAATGGAATTATTTTG
AAGCTGAAGTCATGCTGAGATTAATAGTGCGATTACGAAATCTGGTAGAAAA
GATATCCTACGAGGTTTTAGAGCTGTGTTGTTTCGAATGGTTCCAAAACTGAT
GTTAATGGGCACAAATTTTCTGTCAGGTTTTAGAGCTGTGTTGTTTCGAATGG
TTCCAAAACCCACATGCAATCGCAGCCTTTGTACTCGCAGTTTTAGAGCTGT
GTTGTTTCGAATGGTTCCAAAACTATCCCAGCTTTTGACGCAACGCTCGGAA
AGTTTTAGAGCTGTGTTGTTTCGAATGGTTCCAAAACtgagaccagtctcggaagctca
aaggtctcGTTTTAGAGCTGTGTTGTTTCGAATGGTTCCAAAACTTAATACAGGT
TTTTACAAAAGCTTTACCATGTTTTAGAGCTGTGTTGTTTCGAATGGTTCCAA
AACCAGAACACGCAAGAGTGCAAACGTTAGCTCGTTTTAGAGCTGTGTTGTT
TCGAATGGTTCCAAAACggtcataacctgaaggaagatctggatcctaatgaattcatctgcagggg
cccatcagtctgacgaccaagagagccataaacaccaatagccttaacatcatccccatatttatccaatattcgt
tccttaatttcatgaacaatcttcattctttcttctctagtcattattattggtccattcactattctcattcc
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